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1. INTRODUCTION 
 
“When the stem of a flower gets slightly deviated, 
The florescence doesn’t diminish 
When the sugarcane stalk is deviated, 
The sweetness flows 
When on iron rod is bent,  
It controls even on elephant, 
But, when a nerve gets bent, what can be done?” 
 
 
  This is old tamil saying, which the siddha healers challenged! 
 
 The ultimate purpose of any scientific research is to bring solutions to human 
problems.  The science of contemporary age witnesses science of different turn. Our 
way of relying on technology and mathematical modeling has turned that attention to 
things that have little or nothing to do with day to day concerns of the human race. 
The ancient siddhars speak of numerous remedies solving basic human problems, 
using everything available in the habitat. This medicinal knowledge remains 
unsurprised in the entire world. Our current day problems such as cancer and 
HIV/AIDS seen identical to their descriptions of certain diseases for which they have 
also prescribed healing methods and treatments. The present research aims to analyze 
the medicinal utilization of GANDHAGA PARPAM and it’s medicinal activities like 
anti-cancerous, anti-oxidant and anti-inflammatory. 
 
 Siddha traditional system of medicine is widely being practical in the 
tamilnadu and the concept pertaining to drug ingredients are from plant (Mooligai), 
Mineral(Thathu), Metals and Animal(Jeevam) origin. 
 
Cancer (Yoni putru) is one of the leading causes of mortality world wide and 
the burden is increasing day to day. This dreadful disease existed in our society from 
time immemorial and the way of management including therapeutic aspects has been 
widely described in classical siddha texts. Selected GANDHAGA PARPAM which is 
quoted in agasthiyar vaithiya vallathy 600 published by CCRS-pub.15.   
 
The objective of the present study is to analyses the GANDHAGA PARPAM’S 
therapeutic activities to be utilized for the treatment of cancer and inflammation. The 
hypothesis of the research is to prove that. GANDHAGA PARPAM’S therapeutic 
activities like anti-cancerous, anti-inflammatory and anti-oxidant has shown better 
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results in the cancer and inflammation treatment comparing to some of the standard 
modern drugs for the same. Hence the present research is a unique one in creating 
awareness of the siddha herbo mineral drug and paves way for further research in the 
utilization of GANDHAGA PARPAM to cure the modern drug contagious disease.    
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2. AIM AND OBJECTIVES  
AIM 
  The aim of this present study is to scientifically validate traditional siddha 
medicine Ganthaga parpam for its Anti-cancer, Anti-oxidant, Anti inflammatory 
activities. 
 
OBJECTIVES 
 The main objective of these studies to collect various literatures which 
includes traditional siddha literatures basic modern aspect of the test drug and 
the diseased view. 
 To prepare the drug according to siddha classical literature illustrations to 
standardize the drug by appropriate physico-chemical analysis. 
 To analyse the drug chemically for reduction of metals, minerals to access the 
safety profile of the drug by acute and chronic oral toxicity profiles of 
Ganthaga parpam according to OECD guidelines. 
 To evaluate the anti-cancer activity of the test drug Ganthaga parpam by 
invivo Dalton’s Lymphoma Ascites method. 
 To access anti-oxidant activities of the test drug Ganthaga parpam by using 
invitro DPPH free radical scavenging method. 
 To enumerate the Anti inflammatory activity of test drug Ganthaga parpam 
by using Carrageenan induced hind paw edema method. 
 To evaluate exact bio-chemical content of Ganthaga parpam by using various 
standard protocol. 
 To evaluate the mineral content of Ganthaga parpam by various instrumental 
analysis. 
 To evaluate the efficacy of the drug Ganthaga parpam by various analysis. 
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3.REVIEW OF THE LITERATURE 
3.1. SULPHUR – gf<kgl<< << << <!
 
3.1.1. GUNAPADAM ASPECT : 
SOURCE 
  A non-metallic element found free in beds of gypsum and in a state of 
sublimation in regions of extinct volcanoes; also in combination with several ores 
called pyrites, as sulphates and sulphides of iron, copper, lead, zinc, mercury etc. It is 
a constituent of various vegetable and animal substances such as albumen etc. It is 
obtained by roasting, fusion or by sublimation. 
More than 98 per cent of the native sulphur produced in the United States at 
this time comes from deposits in Louisiana and Texas, Nepal, Afghanistan, Kashmir, 
Burma etc. In India it is found in combination with other metals, minerals, herbal and 
animal products. 
Naturally Occurred as a sublimation product at volcanic fumaroles; a product 
of the activity of biological micro-organisms; as a result of low oxidation potential 
and highly acidic chemical reactions in mineral deposits; formed by the 
decomposition of sulfides, especially pyrite, during mine fires; found in sedimentary 
rocks. 
Ganthagam (Sulphur) in siddha medicine  
Siddhar Bhogar classified the metals and minerals into four groups in his book 
“Bhogar karasara thurai” They are,  
1. Metals (Ulogam)-12 
2. Toxins (Padanam)-64 
3. Minerals (Karasaram)-24 
4. Hydrochemicals (Uparasam)-120 
  “Ganthagam”or Sulphur is one among the Padaanam. Sulphur is a crystalline, 
non-metal used in the preparations like Rasayanam, mathiri, Mezhugu, Parpam and 
Chenduram as major ingredients in Siddha therapeutics.   
In Siddha medicine, it was clinically used as a therapeutic ingredient in Skin 
care therapies. In solid state, it possesses bitter and astringent.  
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Types of Ganthagam: 
 There are four types of ganthagam, which has been discussed in Siddha 
literatures. They are as follows,  
1. Pirappu gandagam, 
2. Kozhi thalai gandagam, 
3. Vana Kendhi vaipu, 
4. Vaipu gandagam,  
Pirappu gandagam 
It occurs naturally in mines and rocks and specially this type of ganthagam can 
be used directly for the medicinal preparation after the definite purification process as 
mentioned in literatures. Exclusively which is originated in mountain rocks.   
Kozhi thalai gandagam 
The term suggests that it resembles like a red coloured cock crown. The 
vaippu ganthagam, Kozhi thalai gandagam  & Vana kendhi gandhagam are the by-
products of Pirappu gandhagam.  
Classification based on Characteristic features  
 Nellikai gandhagam has widely used in the siddha medicinal formulations. 
Pagai sarakku for gandhagam is Sembu (Copper). Natpu sarakku for gandhagam is 
Rasam (mercury).  
Traditional literary names for ganthagam 
Traditionally Sulphur/ganthagam is known with other names like 
Ghandagam, Kaarizhai Natham, Parai natham, Parai Veerayam, Atheetha prakasam, 
Beejam, Selvi vindhu, Sakthi, Sakthi peesam, Chenduraa thrrathi, Theviuram, 
Natham, Narram, Parai natham, Ponnvarni, Rasa sronitham.  
Kozhi thalai kanthagam  also named as Kozhiyin Kudakar, Suga thundam, 
Sigappu Kenthi, Shanathil Sithi, Yoha sithi, Tharuvon, Sathakkaranthi, Aanathavalli, 
Karpagam, Porkami etc.  
Ganthagam- Comparison with Mother Nature 
liki<!lgju!uti<h<hK!Ohiz<!dml<jl!
bikvuigk<!Okx<xq!big<jgbqeiz< –Verse of Theran Porut panbu nool!
The drug ganthagam has compared with the Mother Nature. It is like the 
diseases could be cleared by the medicines as like how a mother nurtures their child 
during their childhood caring period.  
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CHARACTERS 
The gandhagam are again classified based on its special characteristic features 
like colour, odour, shape etc. Here the classical literatures were separated based on its 
colour.  
  It is of four types namely 
1. White coloured gandhagam, which is ideal for the treating diseases 
2. Golden coloured (nellikai gandhagam). 
3. Colour of crow i.e shiny black. 
4. Red as that of beak of parrot. 
(1) The white variety known as roll sulphur is found in sticks about two inches in 
width and 3 to 5 inches long; the taste is bitter and astringent and the smell is 
nauseous. It is very brittle; it is somewhat sticky to touch. It being inferior to the 
yellow variety is preferred for external application. 
(2) ‘Yellow variety or vitreous or precipitated sulphur or Amlasar gandhaka, occurs in 
semi-transparent crystals resembling the translucent ripe fruits of the Amalaki. 
This is employed for internal use in combination with mercury. 
(3) The black variety, i.e., Sublimed sulphur (Gandhak-na-Phul) is a purified form of 
sulphur and is prepared by washing Gandhaga in milk. It is first dissolved in an 
iron ladle smeared with butter and then gradually poured into a basin of milk. 
(4) The red variety is called Rati Hirakasi or Lal gandhak; it occurs in small flat or 
irregular crystalline pieces of a shining orange-red, purple or brick dust colour. 
The taste is acrid and bitter. It burns with a faint blue flame and emits the smell of 
sulphur. 
  In addition, Gooseberry sulphur(Nellikkai Gandhagam) and stick 
sulphur(Vaana Gandagam) have been mentioned in most of the text books of ancient 
siddhamedicine. Gooseberry sulphur is the one which is often used in medicinal 
preparations. 
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SYNONYMS : 
Traditionally Sulphur/ganthagam is known with other names like 
Ghandagam, Kaarizhai Natham, Parai natham, Parai Veerayam, Atheetha prakasam, 
Beejam, Selvi vindhu, Sakthi, Sakthi peesam, Chenduraa thrrathi, Theviuram, 
Natham, Narram, Parai natham, Ponnvarni, Rasa sronitham.  
Kozhi thalai kanthagam  also named as Kozhiyin Kudakar, Suga thundam, 
Sigappu Kenthi, Shanathil Sithi, Yoha sithi, Tharuvon, Sathakkaranthi, Aanathavalli, 
Karpagam, Porkami etc.  
- Gunapadam Thathu Jeeva Vaguppu 
nfe;jfj;jpd; Ngh;jidNa $wf;NfS nre;jNfh nfe;jkh jdKkhFk;; ; ; ; ; ; ; ;; ; ; ; ; ; ; ;; ; ; ; ; ; ; ; 
fj;jp nghd; tw;zpahq; fhhpio ehjq;ftp FUj;jQ; rTfe;jp uhf RNuhzpjq;; ; ; ; ; ; ; ; ;; ; ; ; ; ; ; ; ;; ; ; ; ; ; ; ; ; 
fdp rj;jp jd; khjf; Fz ryhFe; jkdpakhk; ehWk;G+ gl;rkhFk;; ; ; ; ; ; ; ;; ; ; ; ; ; ; ;; ; ; ; ; ; ; ; 
nre;jpahQ; nre;J}uj; jhjpahFQ; nrg;gpa Njhh; Ngnuy;yhq; nfe;jfKkhNk; ; ; ; ; ; ; ; ; ;; ; ; ; ; ; ; ; ; ;; ; ; ; ; ; ; ; ; ;  
-Nghfh; epfz;L; ;; ;; ;  
fe;jp nghd;th;zq; fhhpio ehjkhk; me;jpg ehWk;G+ tjp ur RNuhzpjhk;; ; ; ; ; ; ; ;; ; ; ; ; ; ; ;; ; ; ; ; ; ; ; 
je;jpa rj;jp jd; khjf; Fzr;ryhk; ge;jpa nfe;jp ; ; ; ; ; ; ; ;; ; ; ; ; ; ; ;; ; ; ; ; ; ; ; ghpghi~ ehkNk” 
 -rl;lKdp epfz;L; ;; ;; ;  
VERNACULAR NAMES  
 Sans.  :  Gandhaga  
Eng.  :  Brimstone, Sublimed Sulphur  
Hind.  :  Gandak, Gundhak  
Ben.  :  Gandrak, Gandhak, Kush  
Mal.  :  Gendagum  
Tam.  :  Gandakam  
Tel.  :  Gandhagam  
Punj.  :  Gandhak, Kibrit, Anwlasar, Gogird 
Arab.  :  Kibrika  
ORGANOLEPTIC CHARACTORS  
Colour  : Yellow 
Potency : Hot  
Taste  : Bitter and astringent  
ACTIONS 
 Laxative 
 Tonic 
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 Antiseptic 
 Alterative 
 Diuretic 
 Insecticide 
  Sulphur when taken internally and in small doses becomes absorbed and may 
be excreated through  the sweat, milk and urine. It has a specific action on the rectum 
and increases haemorrhoidal secretions. In large doses it acts as a purgative. 
 
TYPES AND ITS GENERAL PROPERTIES: 
Nellikkai Gandhagam (Gooseberry Sulphur): 
“ney;ypf;fha; nfe;j fj;jp ndwp Nfsha; fTrp  
Fd;kk;ty;yjhk; thA Fl;lk; typtplq; fLq; - fpue;jp  
nrhy;ypLQ; Ruq;fnsy;yhe; njhiye;jpL nkd;W Kd;dh;gy;tif  
Kdpth; rpj;jh; gfh;e;jthf flq;fs; nrhy;Yk;” 
- gjhu;j;j Rlhkzp 
 
“ney;ypf;fha;f; fe;jpf;F ePs;gjpnzd; Fl;lke;jk;  
ty;iy ftpirFd;k thAfz;Nzha; - nghy;yh  
tplf;fbtd; NkfNeha; tPW fuk; Ngjp  
jplf;fpuf zPfgk;Nghe; Njh;.” 
!! ! .!G{himl<!kiK!sQu!uGh<H 
  This is considered to useful in the treatment of 18 types of skin diseases, liver 
enlargement, abdominal distension, eye diseases, chronic venereal diseases, chronic 
diarrhoeas, gastric ulcer, poisonous bites, fever due to vatha, chronic dysentry etc. 
 
Vaana Gandhagam (Stick Sulphur): 
“thzf; Foha;f;fe;jp thridiaf; fz;lTld;  
fhzf; fpUkp nrhwp fhzhthk; - NjhZk;  
ngUtpah jpf;$l;lk; NgUkj D}ypd;  
kUtpah Oq;nfhbNa tho;j;J.” 
 
“khjh; kfit tsh;g;gJNgh NyAlk;ig  
ahjuth fj;Njw;wp ahf;ifapdhy; - kPjhf  
Nktp alh;Nehapd; ntg;gj;ij khw;Wjyhw;  
NwtpAu nkd;gJly; Njh;.” 
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  This sulphur is useful to control the pathogenic micro organisms in the blood.  
It is also useful in the treatment of chronic joint disorders, scabies, asthma, heart 
attack, cough, anorectal diseases, leprosy etc. 
 
PURIFICATION OF SULPHUR: 
1. The exudate obtained from outer shell of tamarind fruit (210 gm) is collected 
and placed in a mud pot. Old rice water fermentation, sour butter milk and the 
juice of mushroom (210 gm each) are also poured in the pot. The pot is 
covered with a cloth over which 3.5 gm of sulphur is placed and the pot is 
covered with a lid. The pot is heated for about 6 hours; the purified sulphur 
settles down. 
2. The kalkam of Lawsonia inermis is mixed in cow’s curd and placed in a mud 
pot.  The mouth of the pot is covered with a cloth. Sulphur is placed over this 
cloth.  The pot is covered with another pot and burried in the ground. The 
outer pot is subjected to puda with five dung cake. The sulphur which melts 
and settles down is collected. This procedure is repeated for 7 times. 
3. Sulphur is placed in an iron spoon. A small quantity of cow’s butter is added 
and the spoon is heated till the butter melts; this mixture is immersed in 
inclimed position in cow’s milk. This procedure is repeated for 30 times to get 
purified sulphur.  Each times, fresh milk is to be used. 
4. Sulphur is melted in the stem  juice of plant  tree for ten times to get it 
purified. 
TRADITIONAL USES 
• Sulphur is given with mercury to treat in almost all diseases. 
• Sulphur with Jaggery or cream of Milk, is given to treat diseases like 
haemorrhoids, porolaps and stricture, also in chronic skin diseases; 
• In skin diseases sulphur is used both internally and externally. 
• Sulphur and Yavakshara (Hordeum vulgare- Barley) mixed with mustard 
oil is applied in pityriasis, psoriasis, etc. 
• In chronic skin diseases a confection of sulphur called Ganthaka rasayana 
is used as an alterative.it is given with hot water before every meal, in 
acute leprosy, has been beneficial. 
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TOXIC SYMPTOMS OF GANDHAGAM 
  Sulphur, without proper purification, if taken in an exceedingly high dose, or 
if taken in the medicinal dose for a certain period of time, causes poisoning. It 
produces the following diseases e.g. skin diseases, loss of semen and beauty,general 
debility etc. 
ANTIDOTE 
• Cow’s milk with cow’s ghee, required quantity to be administered for seven 
days to detoxify Sulphur poisioning. 
• The decoction to prepared from in equal quantity of Cassia auriculata root, 
Gynandropsis gynandra root, Zingiber officnale root, Gossypiun herbaceum 
root, Mesua nagassarium root and Indigofera tinctoria root. 
• The decoction to prepared from  equal quantity of Piper nigrum, Cuminum 
cyminum and Indigofera tinctoria root. 
• Nelumbo nucifera seeds grinded with coconut water and filtered. 
OTHER PREPARATION : 
1. Ananda Bairavam Mathirai 
Dosage   :  1 to 2 pills twice a day. 
Adjuvant  :  honey or ginger juice. 
Indications  :  fevers and janni 
 
2. Ashta Bairavam  
Dosage  :  1 pill twice a day 
Adjuvant  :  breast milk, honey, lavanga decoction, 
Indications  :  fevers, doshams, vishams. 
3. Gandaka Mezhugu  
Dosage  :  2 to 5gms, twice a day. 
Indications  :  vegu-moothram, sori, sirangu, kushtam,moolam,etc. 
4. Gandhaga Sudar Thailam  
Dosage  :  1 to 4 drops   
Indications  :  venkushtam (leucoderma), megapun(syphilitic and  
other chronic ulcers) 
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5. GANDHAGA PARPAM :  
Dosage  :  ¼  to  ½ gms 
Adjuvant  :  ghee or butter. 
Indications  :  skin diseases, such as sori, themal,meghapadai,  
kushtam, mathumegam, swasam, kshayam, moolam, 
bagandaram, etc. 
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SULPHUR : 
3.1.2GEOLOGICAL ASPECT : 
  Sulphur is one of the most abundant and ubiquitous elements in living things. 
It is present in organic materials throughout the universe. 
Name    :  Sulphur 
Symbol   :  S 
Other name   :  Brim stone  
Atomic Number  :  16  
Atomic weight  :  32.064+/-0.003 
Melting point   :  119-120C 
Boiling point   :  44.601C 
Valencies   :  2,4,6 
Crystal System   : Orthorhombic 
Habit     : Crystals common; typically dipyramidal;  
thick tabular on {001},also massive, in 
spherical or reniform shapes, incrusting. 
Twinning    :  Rare on {011}  
Cleavage    :  {001}, {110} indistinct.  Conchoidal to  
uneven. 
Hardness    :  1½ - 2½. 
Tenacity    :  Brittle to slightly sectile. 
Specific Gravity   :  2.07 
Color And Streak  :  Yellow to yellowish brown. 
Storage   :  Store in closed bottle at ambient  
temperatures 
Precautions   :  Chronic inhalation of dust can cause  
irritation of the mucous membrane. 
SOURCE: 
Organic: 
 Sulphur containing amino acids cystine, cysteine and methionine 
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Cysteine: (Amino –thio propionic acid)
 
Cystine: (Dicysteine) 
Methionine: (amino methylthio 
Inorganic 
   Sodium, Pottasium, and Magnesium sulphates.
Occurrence:  
  Native sulfur occurs in regions of recent volcanic activity where it has been 
deposited as a direct sublimation product from volcanic gases, has 
incomplete oxidation of hydrogen sulfide from volcanic sources,or has resulted from 
the decomposition of hydrogen sulfide in thermal spring waters. It also occurs in 
sedimentary sequences that contain sulfates along with organic materials.
In the combined state sulphur occurs as
1.Sulphides and Sulphates
 Sulphides: Eg- 
   
 Sulphates: Eg- 
 Sulphur occur in any organic compounds viz,in animal and vegetable 
products, onion, garlic, mustard, raddish, hair, many oils, Egg white, protein etc. 
2.Sulfonamides 
  The anti microbial compound containing sulfonamide group (SO
called sulfonamides. They are effective against a variety of Gram
Negative and certain Chlamydia. They are mainly bacteriostatic but occasionally in 
 
 
 
–n-butyric acid) 
 
 
 
 
Copper pyrites(CuFeS2) 
 Mercury Sulphide (HgS) Cinnabar 
Gypsum(CaSO42H2O) 
   13 
been formed by  
 
 
2NH2) are 
-Positive, Gram-
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very high concentrations particularly in the urinary tract, they may act as bacterial 
compounds. 
Mode of action of sulphur drugs 
 All higher animals and number of micro-organisms are unable to synthesize 
certain essential nutrients like vitamins, unsaturated carboxylic acids, certain amino 
acids etc.P-amino benzoic acid is needed by the enzyme which are sensitive to sulpha 
drugs.P-amino benzoic acid is needed by the enzyme within those bacteria for the 
synthesis of folic acid. 
 Drugs, which inhibit the growth of any micro-organism are termed anti 
metabolites. Sulpha drugs are anti metabolites for the bacteria, which need P-amino 
benzoic acid for the synthesis of folic acid. Sulphanilamide acts as an inhibitor of 
those enzymatic steps, which are involved in the synthesis of folic acid by the 
bacteria. 
 This is because the bacterial enzymes are unable to distinguish between the 
molecule of P-Amino benzoic acid and that of sulphanilamide there being a close 
structural similarity between the two sulphanilamide thus inhibits the activity of the 
bacterial enzyme, which is therefore unable to synthesize requisite folic acid essential 
for living organisms resulting in the death of  bacteria. Humans do not synthesize 
their own folic acid and get it from dietary sources, they are unaffected, therefore by 
sulpha drugs. 
Associations :  
  It is commonly associated with titanium, vanadium, manganes, coppers, silver, 
strontium, boron, zinc, zinconium, lead, chromium, arsenic. 
Bio- Chemistry 
 Sulphur a nutritionally essential element is present in all cells of the body, 
occurring mainly in protein, in the form of sulphur containing amino acids. It is 
present in certain enzymes, hormones, chondroitin sulphur acid of cartilages and 
tendons and keratin of hair.  
Sulphur in blood: 
 The total sulphur in blood (plasma) averages about 3.4mgm% this is present in 
3 distinct forms 
1.In organic sulphate 0.5-1.1mg/100ml 
2. Neutral sulphate 1.7-3.5mg/100ml 
3. Ethereal sulphate 0.1-1.0mg/100ml 
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Absorbtion 
Sulphur in food is ingested in 2 forms. 
1. As inorganic sulphate of sodium, potassium and magnesium 
2. As organic sulphate from sulphur containing amino acids, glycoprotein’s and 
chondroition sulphuric acid. 
Metabolism 
  In the liver, sulphur undergoes the following changes 
 Most of the organic sulphur is oxidized to inorganic sulphates(SO4).But a 
small portion escapes in oxidation. The un oxidized sulphur is utilized for the 
formation of sulphur containing substances like insulin, anterior pituitary hormones. 
And the rest excreted the urine as neutral sulphar.  
Morphological features:   
  Colour, low hardness, brittleness, melts at 113, burns at 270 in air with a blue 
flame, yielding sulfur dioxide; insoluble in water and unaffected by most acids, 
soluble in carbon disulfide and some oils. 
Importanat Therapeutic Uses 
• Urinary tract infections 
• Acute bacillary dysentery 
• Meningo coccal meningitis  
• Haemophillus influenze meningitis 
• Chancroid 
• Trachoma and inclusion conjunctivitis 
• Used as a prophylaxis to prevent attacks of streptococcal tonsillitis in patients 
who have recovered from rheumatic fever. 
Adverse reactions 
1. Intolerance 
  This usually becomes apparent within 1 week but can occur at anytime during 
the drug administration. The commonest allergic symptoms are drug fever, skin rash 
usually morbili form in type, eosinophilia, Rash is often accompanied by 
conjunctivitis. 
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2. On urinary tract 
  In the presence of acid urine, the acetylated form of the drug may be  
precipitated mainly in the collecting tubules and calyces. This causes renal irritation 
leads to obstruction of the urinary flow and may precipitate cause renal colic. 
Crystaluria, albuminuria, and haematuria can occur leading to the development of 
oliguria and anuria. 
 
3. On haemopoietic system 
   The haemopoietic toxicity includes agranulocytosis, thrombocytopenia 
causing petechiae, haematuria and epistaxis,rarely aplastic anaemia. 
 
4. Miscellaneous 
 These include central nervous system disturbances like confusion, depression, 
ataxia, tinnitus, fatigue and acute psychotic episodes. These disturbances are 
commonest in children than in rarely peripheral neuritis may occur.   
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3.1.3.LATERAL RESEARCH 
Anti-Cancerous Activity of Rasaoushadhi  
Volume : 3 | Issue : 12 | December 2014 • ISSN No 2277 - 8179 Research Paper 
Medical Science 
ABSTRACT 
   Rasashastra is a branch of Ayurveda deals about the minerals, metals, 
precious stones, poisonous herbs having therapeutic property and their processing 
techniques to prepare medicine which are known as Rasaushadhis. Pharmacopoeia of 
‘Ayurveda’ comprises of drugs derived not only from herbs but also from minerals, 
metals and animal products. Rasaushadhis occupied superior status among the 
Ayurvedic Chikitsa due to their high therapeutic potency in eliminating dreadful 
diseases and also for rejuvenation purposes. Hence, in field of treatment, Ayurvedic 
Scholars has given the crown of kingdom to Rasa-vaidyas among tri-vidhavaiyas. 
Nityanada rasa is one of the Rasousahdhi used in the management of Arbuda. In this 
study we done the physic-chemical analysis and qualitative analysis for the Nityanand 
rasa tablet. We got the result of physico-chemical analysis of Nityanand rasa. 
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3.2 CLEISTANTHUS COLLINUS – yMg<ge<< << << <!
3.2.1 GUNAPADAM ASPECT 
  Synonyms :  Odukku,Oddanthalai,Oduvan,Oduvai,Oduppai,Sittoduvai 
Vernacular names 
Eng : Karra 
Tel : Vadisaku 
Mal : Odukkuhera 
Kan : Kadise 
San : Bhallataka-Bijam 
Hin : Bhilawan 
Part used 
 Leaves, Latex  
Organoleptic character 
Taste (Suvai)   : Bitter, Punjent (Kaippu, Karppu) 
Potency (Thanmai)  : Hot(Veppam) 
Bio-Transformation (pirivu) :    Punjunt ( Karppu) 
Action 
 Deobstruent 
Gentral Characters 
It cures Abcess and Lymphnode Enlargement. 
Toxic symptoms 
• Ingestion of its leaves or a decoction of its leaves causes hypokalaemia and 
cardiac arrhythemias, metabolic acidosis, hypotension and hypoxia  probably 
due to distal renal tubular acidosis and toxic induced  vasodilation. 
• Hypokalaemia  and acidosis probably also induced rhabdomylosis resulting in 
myoglobin -  uric  - renal failure, neuromuscular weakness. 
Anti-dote : 
  Multi dose – Activated charcoal reduces mortality, N-acetyl cystein has been 
suggested as a possible antidote for Cleistanthus collinus poisoning. 
Traditional uses 
 The latex of Odukkan is applied  externally for abcess it subsides day by day. 
 Odukkan leaves grind well and applied as  pattru for externally swelling. 
 Odukkan leaves juice melted in ganthagam. 
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Odukkan  in other preparations: 
1. Kuthupatatharkku  (Stab wounds) 
• For stab wounds latex of Euphorbia lingularia applied externally 
along with lemon fomentation on 3rd day 
• Odduvi ver  (Clestanthus collinus root) 
• Siru Thambala Ver (Mutilla occidentalis) 
• Nannari ver (Hemidesmus  indicus) 
• Kirambu (Syzygium aromaticum) 
• Sirupulladi ver (Desmodiuim triliflorus) 
• Sitrelam (Eletterai regains) 
• Amanakku vithu (Ricinus communis seed) 
• Maruthu (Terminalia arjuna) 
• Vembadampattai 
 Process of preparation: 
  All the ingredients are taken in equal amount made into powder then mixed 
with  sesame oil and place the vessel in low till it reach oil consistency. Then cooled 
and applied on stab wounds. 
2.  Punnukku Marundhugal: 
• Nilakumizh (Gmelina asiatica) 
• Oduvan  (Clesthanthus collinus bark) 
• Kambipisin (Gardinia gumnifera) 
• Vembadampattai  
• Indu (Mimosa paniculata) 
• Siru Thambala Ver (Mutilla occidentalis) 
• Athimathuram (Glyzyrhiza glabra) 
   All the ingredients are made into powder and mixed with gingelly oil and 
place the vessel in low flame till it reach air consistency. 
Uses: 
  For wound due to weapons. For weight loss due to wounds caused by weapon 
the bark of Vembadampattai is smashed and soaked in hot water and use the water to 
bath. 
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ODUKKAN (Cleistanthus collinus)  
3.2.2 BOTANICAL ASPECT 
Taxonomical classification 
Kingdom : Plantae 
Division : Angiosperms 
Class  : Magnoliopsida 
Subclass : Rosidae 
Order  : Euphorbiales 
Family  : Euphorbiaceae 
Sub Family : Phyllanthoideae 
Genus  : Cleistanthus 
Species : C.collinus 
Habitat 
 Is a plant species first described by roxburgh,with is current name after 
Bentham and Hooker. It’s included in the family phyllanthaceae. The IUCN 
categorizes this species as vulnerable. No subspecies are listed in the catalogue of life. 
Description 
Habit 
 Cleistanthus collinus is a toxic moderate sized deciduous trees,15m high.  
Leaves 
 Leaves simple, alternate, distichous; stipules lateral, 2-3 m long, linear; petiole 
3-10 mm long, puberulous to glabrous, slender; lamina 3-11.5 x 1.5-8 cm, elliptic, 
suborbicular, obovate or acute, apex round, retuse or apiculate, margin entire, 
glabrous, glaucous beneath, chartaceous; lateral nerves 4-8 pairs, pinnate, slender, 
prominent, intercostae reticulate, prominent. 
 Flowers 
 Flowers unisexual, yellowish-green, in glomerules borne on main leafy 
branches and short lateral branchlets; the male 3-5 flowered; females upto 3 flowers; 
bracts 1.5-2 mm long, subulate; male flowers: pedicels 1-2 mm long, puberulous, 
calyx tube shortly obconic, lobes 5, occasionally 6, 3-4 x 1-2 mm, triangular-oblong 
or lanceolate-oblong, adpressed fulvous pilose outside; petals 5, linear; disc annular, 
shallowly lobed, glabrous; staminal column ca.1.5 mm; anthers oblong; pistillode 
ovoid; female flowers: pedicel 0.5 mm long, grey-pilose; calyx tube obconic, ca.1 mm 
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long; sepals 4-5 x 1-3 mm, triangular-lanceolate, scattered grey-pilose outside; petals 
ca. 2 x 1 mm, subulate; disc shortly cupular-annular; ovary superior, 2-2.5 x 2-3 mm, 
subglobose, glabrous; styles 3-4 mm long, almost free or basal column ca.1.5 mm 
long, shortly to deeply bifid above, recurved. 
Bark  
  Bark dark brown, nearly black, rough, flaking off in rounded thick scales, 
blaze red; branchlets, terete. 
Fruits and seed 
 Fruit a capsule, 18-22 x 17-22 mm, subglobose or wide oblong, truncate at 
apex, shallowly 3 lobed and 3-angled, glossy, glabrous, black or dark brown when 
dry; seeds 3, globose, black; pedicels 0.5-1.5 mm long.  
Chemical constituents 
  It contains Clestianthin-A, Clestianthin-B, Collinusin, Oduvin-Gulucoside, 
Sapponin, Tannin 
Toxic constituents 
  Analyses of extracts from the plant, including the leaves, reveal a complex 
group of compounds. The toxic active principles in the leaves are arylnaphthalene 
lignan lactones—Diphyllin and its glycoside derivatives Cleistanthin A and 
Cleistanthin B; and Collinusin Diphyllin, Cleistanthin A and B were collectively 
known as “Oduvin” in the past. In addition, the lignans Cleistanthin C, Cleistanthin D 
and Cleistanone, are present.The toxicity of the plant has been attributed primarily to 
Cleistanthin A and B. 
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  These toxic principles, the arylnaphthalene lignans, are detected in acetone 
extracts but, are not seen or are present in minimal amounts in aqueous extracts.On 
spectroscopic analysis of aqueous extracts of fresh C. collinus leaves, the other major 
phytoconstituents detected are 3-O-methyl-d-glucose, benzenetriol (pyrogallic acid), 
1.6- anhydro-â-D-glucopyranose (levoglucosan), heptacosane, 2-hydroxy-7-methoxy-
4,5-diphenyl-5 hindeno [1.2-d] pyrimidine and eicosane. 
Therapeutic uses 
• The plant have anti-septic, anti-fungal, insecticidal and larvicidal property 
• The leaf extract act against the pathogens like methicillin resistant, 
staphylococcus aureus (MRSA), enterococcus and candida species. Mostly 
these pathogens are the causative agents for skin infections and urinary tract 
infections. 
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3.2.3 LATERAL RESEARCH: 
 
EVALUATION OF ANTI-CANCEROUS ACTIVITY AND ANTI OXIDANT  
EFFECT OF CLEISTRANTHUS COLLINUS LEAF EXTRACT IN RATS 
 
ABSTRACT: 
  Aqueous, methanol and ethyl acetate crude extracts and fractions were 
prepared using Cleistanthus collinus Roxb. dry leaf powder. All the extracts and 
fractions were subjected to in vitro cytotoxic analysis using mouse 3T3- L1 pre-
adipocytes cell line. Rate of cell proliferation was calculated to determine the anti-
proliferative activity. Aqueous, methanol and ethyl acetate extracts (≥100 µg/ml) 
significantly control cell proliferation at 48 hr incubation. However, fractions 
exhibited higher level of toxicity and affect cell growth even at 50 µg/ml 
concentration within 28 hr incubation. Fractions obtained from methanol extract 
showed cytotoxic effect about 43-76 % at 50-250 µg/ml at 48 hr incubation 
(Concentration necessary to inhibit cell growth at 50 % is ~75 µg/ml). Followed by, 
ethyl acetate fraction exhibited 23-59 % of anti-proliferative activity (Concentration 
necessary to inhibit cell growth at 50 % is ~180 µg/ml). It may be concluded that 
promising fractions of C. collinus with higher toxicity level could be exploited for 
pharmacological purposes.  
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3.3 DISEASE REVIEW 
3.3.1 SIDDHA ASPECT 
Hx<X!uVl<!upq< << << <  (Etiology) 
 
Ciu gjdope;j czTfSz;zy; tiugL Gyhy; kPd; tof;fj; Jz;zy; 
GzHr;rp kpFjypd; ntg;g kPWjy; ntg;g epiyfs; NtWgLgtiu 
mbf;fb GzHjy; xOf;F NehAwy; clyof;NfYjy; mZf;fs; GFjy; 
vD kpit gpwTk; gytifg;gl;l Gw;W Neha;f; fbg;gilahFk;. 
 
- khd;KUfpak; vd;Wk; jkpo; kUj;JtE}y; 
 
  Contaminated foods (fish, mutton), more sexual contact, increased Pitham, 
other climate sexual partner, vellainoi, other foreign infectious organism,etc. 
 
Hx<xqe<!Lx<Gxq!< < << < << < <  (Premonitary symptoms) 
 
Gw;Wj; Njhd;wple; jpdT Njhd;wy; mt;tplk; Giugl;nldj; Njhd;wpLjy; 
jirfope; jfty; jsHr;rp Njhd;wy; cly;epiy NtWgl; nld;dj;Njhd;wy; 
Gw;Wk; cWg;gpd; njhopy; Fiwe;jpLjy; Mw;wy; nfLjy; cWg;G Nehjy; 
rptj;jy; fLj;jy; Fj;jy; gpwTk; Gw;WNehapd; Kd;dkhFk;;;; 
 
  Itching, patches, discomfort of the body, loss of energy, pain, redness, 
swelling and etc. 
 
Hx<xqe<!GxqG{l<< < << < << < < (Sign and symptoms of cancer) 
 
rpWf rpWfr; Nrtw; g+g;Nghy $He;J jpuz;L kop jir tsHjy; 
gpzpAw; wplKk; maYk; euk;Gk; kpfTk; Nehjy; jiraope; jpLjy; 
euk;G Kjypa mupf;fg;gLjy; FUjpAk; gOg;G Njhd;wy; xOfy; 
clk;G nkypjy; jLkhw; waHr;rp vDkpit gpwTk; Gw;wpd; FwpNa 
 
  Muscle mass is appear like cock comb, pain present in whole affected part of 
body, wasting of the muscle and nerves, bleeding of blood and brown colour fluid, 
body weight is decreased, etc. 
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GiuNjhd;WjYk; jir jpiwj; jplYk; cl;rij jpusYk; FUjpnahOfYk; 
vspjpw; wPuhg; Gz; Njhd;wplYk; FUf;fs; Nghyj; jirNkw;nwhd;wYk; czT 
whik njhlHe;j Njhd;wYk; mbf;fb apUky; Fuyil Njhd;wYk; Gs;spfs; 
Njhd;wYk; epwk; NtWgLjYk; ePq;fhj; jsHr;rp aaHr;rp Njhd;wYk; Flw;gpzp 
njhlHe;j Njhd;wYk; gpwTk; Gw;WNeha;f;Fk; Kd;dkhjypd; Kw;gl TzHe;J 
Nghjy; khNk 
 
  Patches appear the wound, hardness of muscle, loss of appetite, recurrent 
cough, loss of voice, malaise, dots appear, colour changes, intestinal diseases and etc. 
!
nz<Gz<Hx<xqe<!G{l<!)< < < < << < < < << < < < < Sign and symptoms of Cervical cancer) 
 
my;Fy; thapD kfe;J kUfpDk; Nrtw;g+g;Nghy; moprij tsHjy; 
Nehjy; Fj;jy; rPo;kpf nthOfy; FUjp ntspg;gly; jireuk; gopjy; 
Giugly; vDkpit ngz;Fwpg; Gw;wpd; Fwpnad nkhopg newpgwp GytH 
 
kQVl<?!kQvi?!Ofib<g<Gxq!Q < Q < <Q < Q < <Q < Q < <  (Prognosis) 
 
Gw;W Nehaidj;Jk; nghUe;jg; Ngzpd;;;; mupjpw; wPHtd thFnkd;g 
mWitapw; rpw;rpy mfy;tJ khFk; kpf;f jsHr;rp nkypT ePH Ntl;if 
nghwpfspd; Mw;wyopjy; kaf;fk; fha;r;ry; Njhd;wy; tpf;fnyLj;jy; 
czT nry;yhik cz;lj whik vDkpit gpwTe; jPuhf; FwpAk; 
 
  If select proper treatment to cancer will cure the cancer, surgery may prevent 
the cancer. But malasise, loss weight, thirst, lack of energy, dizziness, fever and above 
all the symptoms when appear to patent, will not relive from cancer. 
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3.3.2 MODERN ASPECT 
INTRODUCTION 
  Cervical cancer starts in a woman's cervix, which is the lower, narrow part of 
the uterus. The uterus holds the growing foetus during pregnancy. The cervix 
connects the lower part of the uterus to the vagina and, with the vagina, forms the 
birth canal. 
  Cervical cancer begins when healthy cells on the surface of the cervix change 
and grow out of control, forming a mass called a tumour. A tumour can be malignant 
or benign. A cancerous tumour is malignant, meaning it can spread to other parts of 
the body. A benign tumour means the tumour will not spread. 
  At first, the changes in a cell are abnormal, not cancerous. Researchers 
believe, however, that some of these abnormal changes are the first step in a series of 
slow changes that can lead to cancer. Some of the abnormal cells go away without 
treatment, but others can become cancerous. This phase of the disease is called 
dysplasia, which is an abnormal growth of cells. The abnormal cells, sometimes 
called precancerous tissue, need to be removed to keep cancer from developing. 
Often, the precancerous tissue can be removed or destroyed without harming healthy 
tissue, but in some cases, a hysterectomy is needed to prevent cervical cancer. A 
hysterectomy is the removal of the uterus and cervix. 
  Treatment of a lesion, which is a precancerous area, depends on the following 
factors: 
 The size of the lesion and the type of changes that have occurred in the cells 
 If the woman wants to have children in the future 
 The woman's age 
 The woman's general health 
 The preference of the woman and her doctor 
  If the precancerous cells change into cancer cells and spread deeper into the 
cervix or to other tissues and organs, then the disease is called cervical cancer. 
  There are 2 main types of cervical cancer, named for the type of cell where the 
cancer started. Other types of cervical cancer are rare. 
 Squamous cell carcinoma makes up about 80% to 90% of all cervical cancers. 
These cancers arise in the cells on the outer surface covering of the cervix. 
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 Adenocarcinoma makes up 10% to 20% of all cervical cancers. These cancers 
arise in the glandular cells that line the lower birth canal. 
  The squamous and glandular cells meet at the opening of the cervix at the 
“squamocolumnar junction,” which is the site at which most cervical cancers arise. 
  In medical research, the most famous cell line known as HeLa was developed 
from cervical cancer cells of a woman named Henrietta Lacks. 
 
SIGNS AND SYMPTOMS 
  When present, common symptoms of cervical cancer may include: 
 Vaginal bleeding: This includes bleeding between periods, after 
sexual intercourse or post-menopausal bleeding. 
 Unusual vaginal discharge: A watery, pink or foul-smelling discharge 
is common. 
 Pelvic pain: Pain during intercourse or at other times may be a sign of 
abnormal changes to the cervix, or less serious conditions. 
  All of these cervical cancer symptoms should be discussed with your doctor. 
 
SIGNS OF ADVANCED STAGES OF CERVICAL CANCER 
  Cervical cancer may spread (metastasize) within the pelvis, to the lymph 
nodes or elsewhere in the body. Signs of advanced cervical cancer include: 
 Weight loss 
 Fatigue 
 Back pain 
 Leg pain or swelling 
 Involuntary urination 
 Bone fractures 
CAUSES 
  Cervical cancer begins with abnormal changes in the cervical tissue. The risk 
of developing these abnormal changes is associated with infection with human 
papillomavirus (HPV). In addition, early sexual contact, multiple sexual partners, and 
taking oral contraceptives (birth control pills) increase the risk of cervical cancer 
because they lead to greater exposure to HPV. 
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HUMAN PAPILLOMA VIRUS 
  Forms of HPV, a virus whose different types cause skin warts, genital warts, 
and other abnormal skin disorders, have been shown to lead to many of the changes in 
cervical cells that may eventually lead to cancer. Certain types of HPV have also been 
linked to cancers involving the vulva, vagina, penis, anus, tongue, and tonsils. Genetic 
material that comes from certain forms of HPV (high-risk subtypes) has been found in 
cervical tissues that show cancerous or precancerous changes. 
  In addition, women who have been diagnosed with HPV are more likely to 
develop a cervical cancer. 
 
SEXUAL CONTACT 
  Girls who begin sexual activity before age 16 or within a year of starting their 
menstrual periods are at high risk of developing cervical cancer. 
 
SMOKING 
  Cigarette smoking is another risk factor for the development of cervical 
cancer. The chemicals in cigarette smoke interact with the cells of the cervix, causing 
precancerous changes that may over time progress to cancer. The risk of cervical 
cancer in cigarette smokers is two to five times that of the general population. 
 
ORAL CONTRACEPTIVES PILL 
  Oral contraceptives ("the pill"), especially if taken longer than five years, may 
increase the risk for cervical cancer because they reduce the use of condoms. 
 
MULTIPLE PREGNANCIES 
  Having many pregnancies is associated with an increased risk of cervical 
cancer. Among HPV-infected women, those who have had seven or more full-term 
pregnancies have around four times the risk of cancer compared with women with no 
pregnancies, and two to three times the risk of women who have had one or two full-
term pregnancies.  
 
CHRONIC CERVICITIES 
  It is the chronic or persistent inflammation of the cervix, which is the lower 
portion of the uterus. It may be caused by a number of factors, chronic bacterial 
infections due to staphylococcus, streptococcus, E.coli, anaerobic bacteria, chemical 
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or physical irritations, injurys to the vagina, sexually transmitted infection(STIs) such 
as due to Neisseria gonorrhoeae bacterium, and allergies. 
 
DIAGNOSIS 
SCREENING 
  Cervical cancer that is detected early is more likely to be treated successfully. 
Most guidelines suggest that women begin screening for cervical cancer and 
precancerous changes at age 21. 
 
SCREENING TESTS INCLUDE 
  Pap test: During a Pap test, your doctor scrapes and brushes cells from your 
cervix, which are then examined in a lab for abnormalities.A Pap test can detect 
abnormal cells in the cervix, including cancer cells and cells that show changes that 
increase the risk of cervical cancer. 
 
  HPV DNA test: The HPV DNA test involves testing cells collected from the 
cervix for infection with any of the types of HPV that are most likely to lead to 
cervical cancer. This test may be an option for women age 30 and older, or for 
younger women with an abnormal Pap test. 
 
 
 
 
 
 
 
 
 
 
Figure 1: Cervical cancer affected area 
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CONE BIOPSY 
  If cervical cancer is suspected, your doctor is likely to start with a thorough 
examination of your cervix. A special magnifying instrument (colposcope) is used to 
check for a bnormal cells. 
  During the colposcopic examination, your doctor is likely to take a sample of 
cervical cells (biopsy) for laboratory testing. To obtain tissue, your doctor may use: 
 Punch biopsy, which involves using a sharp tool to pinch off small samples of 
cervical tissue. 
 Endocervical curettage, which uses a small, spoon-shaped instrument (curet) 
 A thin brush to scrape a tissue sample from the cervix. 
 If the punch biopsy or endocervical curettage is worrisome, your doctor may 
perform one of the following tests: 
 Electrical wire loop, which uses a thin, low-voltage electrical wire to obtain a 
small tissue sample. Generally this is done under local anesthesia in the office. 
 Cone biopsy, which is a procedure that allows your doctor to obtain deeper 
layers of cervical cells for laboratory testing. A cone biopsy may be done in a 
hospital under general anesthesia. 
STAGING 
  If your doctor determines that you have cervical cancer, you'll have further 
tests to determine the extent (stage) of your cancer. Your cancer's stage is a key factor 
in deciding on your treatment. 
 
STAGING EXAMS INCLUDE 
 Imaging tests: Tests such as X-rays, CT scans, magnetic resonance imaging 
(MRI) and positron emission tomography (PET) help your doctor determine 
whether your cancer has spread beyond your cervix. 
 Visual examination of your bladder and rectum: Your doctor may use special 
scopes to see inside your bladder and rectum. 
STAGES OF CERVICAL CANCER INCLUDE 
 Stage I: Cancer is confined to the cervix. 
 Stage II: Cancer is present in the cervix and upper portion of the vagina. 
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 Stage III: Cancer has moved to the lower portion of the vagina or internally to 
the pelvic side wall. 
 Stage IV: Cancer has spread to nearby organs, such as the bladder or rectum, 
or it has spread to other areas of the body, such as the lungs, liver or bones. 
CANCER SUBTYPES 
  Histologic subtypes of invasive cervical carcinoma include the following: 
Though squamous cell carcinoma is the cervical cancer with the most incidence, the 
incidence of adenocarcinoma of the cervix has been increasing in recent decades. 
 Squamous cell carcinoma (about 80-85%) 
 Adenocarcinoma (about 15% of cervical cancers) 
 Adenosquamous carcinoma 
 Small cell carcinoma 
 Neuroendocrine tumour 
 Glassy cell carcinoma 
 Villoglandular adenocarcinoma 
  Noncarcinoma malignancies which can rarely occur in the cervix include 
melanoma and lymphoma. The FIGO stage does not incorporate lymph node 
involvement in contrast to the TNM staging for most other cancers. 
  For cases treated surgically, information obtained from the pathologist can be 
used in assigning a separate pathologic stage, but is not to replace the original clinical 
stage. 
PREVENTION 
  Cervical cancer can often be prevented by having regular screenings to find 
any precancers and treat them. Preventing precancers means controlling possible risk 
factors, such as: 
 Delaying first sexual intercourse until the late teens or older 
 Limiting the number of sex partners 
 Avoiding sexual intercourse with people who have had many partners 
 Avoiding sexual intercourse with people who are obviously infected with 
genital warts or show other symptoms 
 Quitting smoking 
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  The HPV vaccine helps prevent cervical cancer caused by HPV (see Risk 
Factors). Gardasil 9 is available in the United States for preventing infection from 
HPV-16, HPV-18, and 5 other types of HPV linked with cancer. There were 2 other 
vaccines previously available in the United States: Cervarix and the original Gardasil. 
Both of these are no longer available in the United States. However, these vaccines 
may be in use outside of the United States. 
  To help prevent cervical cancer, ASCO recommends that girls receive HPV 
vaccination. Talk with a health care provider about the appropriate schedule for 
vaccination because it may vary based on many factors, including age and vaccine 
availability. Learn more about HPV vaccination and ASCO’s recommendations for 
preventing cervical cancer. 
  Screening is used to look for cancer or abnormalities that may become 
cancerous before you have any symptoms or signs. Scientists have developed, and 
continue to develop, tests that can be used to screen a person for specific types of 
cancer before signs or symptoms appear. The overall goals of cancer screening are to: 
  Reduce the number of people who die from the cancer, or completely 
eliminate deaths from cancer. 
  Reduce the number of people who develop the cancer. 
 
BARRIER PROTECTION 
  Barrier protection and/or spermicidal gel use during sexual intercourse 
decreases cancer risk. Condoms offer protection against cervical cancer. Evidence on 
whether condoms protect against HPV infection is mixed, but they may protect 
against genital warts and the precursors to cervical cancer. They also provide 
protection against other STIs, such as HIV and Chlamydia, which are associated with 
greater risks of developing cervical cancer. 
  Condoms may also be useful in treating potentially precancerous changes in 
the cervix. Exposure to semen appears to increase the risk of precancerous changes 
(CIN 3), and use of condoms helps to cause these changes to regress and helps clear 
HPV. One study suggests that prostaglandin in semen may fuel the growth of cervical 
and uterine tumors and that affected women may benefit from the use of condoms. 
Abstinence also prevents HPV infection. 
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VACCINATION 
  HPV vaccines are vaccines that protect against infection with human 
papillomaviruses (HPV). HPV is a group of more than 200 related viruses, of which 
more than 40 are spread through direct sexual contact. Among these, several HPV 
types cause genital warts, and about a dozen HPV types can cause certain types of 
cancer cervical, anal, oropharyngeal, penile, vulvar and vaginal. 
  The Food and Drug Administration (FDA) has approved three vaccines that 
prevent infection with disease-causing HPV types: Gardasil®, Gardasil® 9, and 
Cervarix®. All three vaccines prevent infection with HPV types 16 and 18, two high-
risk HPVs that cause about 70% of cervical cancers and an even higher percentage of 
some of the other HPV-caused cancers. Gardasil also prevents infection with HPV 
types 6 and 11, which cause 90% of genital warts. Gardasil 9 prevents infection with 
the same four HPV types plus five additional cancer-causing types (31, 33, 45, 52, 
and 58). 
  Gardasil 9 is the only HPV vaccine available for use in the United States. 
Cervarix and Gardasil are still used in other countries. 
 
NUTRITION 
  Vitamin A is associated with a lower risk as are vitamin B12, vitamin C, 
vitamin E, and beta-carotene. 
 
BRACHYTHERAPY FOR CERVICAL CANCER 
  Larger early-stage tumors (IB2 and IIA more than 4 cm) may be treated with 
radiation therapy and cisplatin-based chemotherapy, hysterectomy (which then 
usually requires adjuvant radiation therapy), or cisplatin chemotherapy followed by 
hysterectomy. When cisplatin is present, it is thought to be the most active single 
agent in periodic diseases. 
  Advanced-stage tumors (IIB-IVA) are treated with radiation therapy and 
cisplatin-based chemotherapy. On June 15, 2006, the US Food and Drug 
Administration approved the use of a combination of two chemotherapy drugs, 
hycamtin and cisplatin, for women with late-stage (IVB) cervical cancer treatment. 
Combination treatment has significant risk of neutropenia, anemia, and 
thrombocytopenia side effects. 
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  For surgery to be curative, the entire cancer must be removed with no cancer 
found at the margins of the removed tissue on examination under a microscope. This 
procedure is known as exenteration. 
 
PROGNOSIS 
  Prognosis depends on the stage of the cancer. The chance of a survival rate 
around 100% is high for women with microscopic forms of cervical cancer. With 
treatment, the five-year relative survival rate for the earliest stage of invasive cervical 
cancer is 92%, and the overall (all stages combined) five-year survival rate is about 
72%. These statistics may be improved when applied to women newly diagnosed, 
bearing in mind that these outcomes may be partly based on the state of treatment five 
years ago when the women studied were first diagnosed. With treatment, 80 to 90% of 
women with stage I cancer and 60 to 75% of those with stage II cancer are alive 5 
years after diagnosis. Survival rates decrease to 30 to 40% for women with stage III 
cancer and 15% or fewer of those with stage IV cancer 5 years after diagnosis. 
  According to the International Federation of Gynecology and Obstetrics, 
survival improves when radiotherapy is combined with cisplatin-based chemotherapy. 
  As the cancer metastasizes to other parts of the body, prognosis drops 
dramatically because treatment of local lesions is generally more effective than 
whole-body treatments such as chemotherapy. 
  Interval evaluation of the woman after therapy is imperative. Recurrent 
cervical cancer detected at its earliest stages might be successfully treated with 
surgery, radiation, chemotherapy, or a combination of the three. About 35% of 
women with invasive cervical cancer have persistent or recurrent disease after 
treatment. 
  Average years of potential life lost from cervical cancer are 25.3. Around 
4,600 women were projected to die in 2001 in the US of cervical cancer, and the 
annual incidence was 13,000 in 2002 in the US, as calculated by SEER. Thus, the 
ratio of deaths to incidence is about 35.4%. 
  Regular screening has meant that precancerous changes and early-stage 
cervical cancers have been detected and treated early. Figures suggest that cervical 
screening is saving 5,000 lives each year in the UK by preventing cervical cancer. 
About 1,000 women per year die of cervical cancer in the UK. All of the Nordic 
countries have cervical cancer-screening programs in place.  
  
   35 PRE CLINICAL  STUDY OF  GANDHAGA PARPAM 
 
EPIDEMIOLOGY 
AUSTRALIA 
  Cervical cancer was the 14th most commonly diagnosed cancer among 
females in Australia in 2013. In 2017, it is estimated that it will remain the 14th most 
commonly diagnosed cancer among females. 
  In 2013, there were 813 new cases of cervical cancer diagnosed in Australia. 
In 2018, it is estimated that 930 new cases of cervical cancer will be diagnosed in 
Australia. 
  In 2013, the age–standardised incidence rate was 6.8 cases per 100,000 
females. In 2017, it is estimated that the age–standardised incidence rate will be 7.1 
cases per 100,000 females. The incidence rate for cervical cancer is expected to be 
highest for age group 35–39, followed by age groups 40–44 and 85+ (Figure 1). 
  The number of new cases of cervical cancer diagnosed decreased from 965 in 
1982 to 813 in 2013. Over the same period, the age–standardised incidence rate 
decreased from 14 cases per 100,000 females in 1982 to 6.8 cases per 100,000 
females in 2013. 
 
WORLD WIDE 
  Worldwide, cervical cancer was the fourth most common cancer among 
females in 2012. There were an estimated 528 000 new cases of cervical cancer, of 
which around 85% occurred in less developed regions. Around 266 000 females died 
of cervical cancer, accounting for 7.5% of all female cancer deaths. About 87% of 
cervical cancer deaths 1 occurred in the less developed regions. 
 
UNITED STATES 
  An estimated 12,900 new cervical cancers and 4,100 cervical cancer deaths 
will occur in the United States in 2015. In the United States, it is the eight-most 
common cancer of women. The median age at diagnosis is 48. Hispanic women are 
significantly more likely to be diagnosed with cervical cancer than the general 
population. In 1998, about 12,800 women were diagnosed in the US and about 4,800 
died. In 2014, an estimated 12,360 new cases were expected to be diagnosed, and 
about 4,020 were expected to die of cervical cancer. Among cancers of the female 
reproductive tract it is less common than endometrial cancer and ovarian cancer. The 
rates of new cases in the United States was 7 per 100,000 women in 2004. Cervical 
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cancer deaths decreased by approximately 74% in the last 50 years, largely due to 
widespread Pap smear screening. The annual direct medical cost of cervical cancer 
prevention and treatment prior to introduction of the HPV vaccine was estimated at $6 
billion. 
 
EUROPEAN UNION 
  In the European Union, about 34,000 new cases per year and over 16,000 
deaths due to cervical cancer occurred in 2004. 
 
UNITED KINGDOM 
  Incidence rates for cervical cancer are projected to rise by 43% in the UK 
between 2014 and 2035, to 17 cases per 100,000 females by 2035. 1 in 135 women 
will be diagnosed with cervical cancer during their lifetime. Cervical cancer in 
England is more common in females living in the most deprived areas. 
 
CANADA 
  In Canada, an estimated 1,300 women will have been diagnosed with cervical 
cancer in 2008 and 380 will have died. 
 
INDIA 
  According to a report 'Call for Action: Expanding cancer care for women in 
India, 2017', cancer among women in India is estimated at 0.7 million. However, the 
real incidence is much more between 1 and 1.4 million per year as many cases go 
undiagnosed or unreported. 
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3.4. PHARMACEUTICAL REVIEW 
PARPAM (CALX)  
Definition: 
  Parpam is equivalent to calx, which is prepared by the process of calcination.  
The correct Tamil translation would be “Neeru” which would mean an ash. 
“Saambal” is another word equivalent to an ash or calx. 
  Metals, uparasas or paashanas are made into white powder by the process of 
pudam, burning, frying, blowing and by grinding them with juices, ceyaneer etc. 
 
hx<h!lgqjl<<< !
uQvk<K!lqg<gju!hx<hr<gOt!–!hvq!
!!! givk<K!lqg<gju!hx<hr<gOt!
hiVg<Gt<!lieqmI!Ofib<Ohig!–!uV!
!!! h{<ckVg<ogz<zi!liOligl<!
uQvgmiiq!–!hq{qg<ogiV!
!!! hivGmiiq!–!uqjsoh!
kQvkmiiq!–!uqjeBM!
!!! $vqg<GP!Ofovik<kK!
OlVg<gqje!hivh<Hxl<!!!!!!!!!!!!!!!!!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Okve<!kV!
!
!! hx<h!lVf<Kgt<!! ;!! LPue<jlBl<!
! osf<K~vr<gt<!! ;! Lg<giz<ue<jlBl<!
! Wjebju! ! ;! -kx<G!Gjxf<k!ue<jlBjmbe!
!
Equipment required: 
 Mortar and pestle. 
 Vessels and spoons to handle liquids. 
 Long ribbons of tough cloth and fine clay. 
 Pairs of shallow earthen discs of identical dimensions. 
 Cow dung cakes, sufficient numbers and well dried. 
 Fine cloth pieces for filtering juices and decoction. 
 Spatulae for handling powders. 
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General method of preparation: 
 The drugs are ground according to the particular recipe, with other drugs, 
juices or decoctions, and the resultant mass is made into small, thin circular cakes and 
dried .When they are well dried, they are taken for calcination.  
The material ready for calcination, is put into an earthen disc described earlier, and 
covered by inverting another disc and sealing the rim with the cloth ribbon one side of 
which is smeared with wet clay. This makes a capsule type crucible. When the seal is 
dry, the capsule is placed in the kiln for calcination. 
 The kiln or “pudam” as it is called in Tamil, is made by digging a pit of 
appropriate dimensions in the soil, and filling it with the recommended number of 
cowdung cakes, which is the fuel. It is better that the interior of the pit is lined with 
bricks, so that the pit could be used repeatedly. 
 Seventy five percent of the recommended numbers of dung cakes are arranged 
in the pit and then the capsule is placed in the centre. The rest of the dung cakes are 
arranged above this and the top is somewhat dome shaped. When some burning 
charcoal pieces are placed on the dome, the dung cakes below them catch fire and the 
fire spreads all around in a uniform manner. 
 The kiln will burn for a long time, until all the dung cakes are burnt and 
converted into ashes. When the kiln cools down, the ashes are very carefully removed 
and the capsule is taken out without damaging the seat. The exterior of the capsule is 
thoroughly brushed to remove the ashes and the seal is scraped off and removed. 
The contents of the capsule are recovered, and the remnants that adhere to the walls 
are gathered by great scraping and brushing. 
 For the complete transformation of the material into “parpam” state, the 
process of grinding, drying and calcination may have to be repeated several times or 
atleast as many times as directed in the recipe. However, the calcination is repeated 
until a satisfactory product is obtained. But in those instances where the number of 
calcinations is definitely indicated, the process should be repeated accordingly, even 
if a satisfactory “parpam” is obtained within a few calcifications. 
 
Colour: 
  In general parpam are always white in colour but Tankaparpam (calx of Gold) 
is light yellow in colour 
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Character and tests for parpam: 
 The final product should not have any glitter or shine. 
 If a small quantity is pinched and rubbed between the thumb and index finger, 
the particles should be so fine as to enter and reside in the furrows and folds. 
 If a pinch of parpam is gently put on the surface of water kept in a container, 
the material should not sink, but it should float.  
 If the parpam is put into a crucible and heated, it should not be reverted into 
its metallic state. 
Preservation and storage: 
 Parpam should be stored in a clean dry and air tight glass containers. 
 
Shelf life: 
 Parpam keep their potency for 100 years. 
 
 Note: 
 The colour effect and fineness of the parpam will be enhanced according to 
the degree of grinding and so it should be ground very finely. 
 If the discs are not well dried, the parpam will not attain the specific colour 
specific for the particular parpam. 
 When the discs (Dried villai) are arranged in the pans they should not be 
heaped up and should not be arranged in more than one layer. Only then the 
heat will react on the material properly. The pans should not be 
disproportionately big when compared to the quantity of the drugs and they 
should not be very deep also. 
 The kiln is constructed by making circular excavations of suitable dimensions 
in places with optimum aeration and the sides are lined with bricks. Kilns 
should not be constructed in places where strong winds blow. 
 Half of the numbers of cow dung cakes are spread at the bottom of the kiln 
and the calcination earthen vessels are placed over this at the centre. The 
remaining cow dung cakes are arranged over this and are to be ignited all 
around. 
 Usually cow dung cakes are used as fuel in kilns. However in some specified 
instances some barks or goat dung and other materials are also recommended. 
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 In cow dung cakes there will be an appreciable admixture of sand or 
mud.Depending upon the degree to which there is such admixture the number 
and weight of the cow dung cakes are increased.One can determine this 
correctly only by adequate practical experience.  
 Materials like sulphur and yellow orpiment which do not withstand strong 
heating are hidden in specified ashed when being calcined. In such cases the 
ash is spread in the pan, the discs placed over and then covered with more ash, 
after which the other pan is inverted over and scaled along the seam. 
 The calcination capsules and the contents there in should be taken only when 
the kiln has cooled down by itself. 
!
!
!
!
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4. MATERIALS AND METHODS 
PREPARATION OF THE DRUG: 
  GANDHAGA PARPAM has been selected from classical siddha literature 
Agasthiyar Vaithiya Vallathy – 600 
  Ingredients of the test drug are Gandhagam, Sittoduvai. 
 
COLLECTION OF THE DRUG 
 The raw drugs Gandhagam were purchased from authorized drug store in 
Nagercoil at Kanyakumari district. 
  The herbal drug Sittoduvai were collected from Salem District. 
 
IDENTIFICATION AND AUTHENTICATION OF DRUGS : 
 The raw materials were identified and authenticated by the experts of PG 
Gunapadam Dept, Government Siddha Medical College, Tirunelveli. 
 The identified raw materials were conserved in the laboratory of PG 
Gunapadam, Government Siddha Medical College, Tirunelveli. 
 
INGREDIENTS 
1) Gandhagam (Sulphur) – S 
2) Sittoduvai Juice (Odukkan) – Cleistanthus collinus (Linn) 
PURIFICATION OF INGREDIENTS 
1) Gandhagam – (Sulphur): 
 Sulphur is placed in an iron spoon.  A small quantity of cow’s butter is added 
and the spoon is heated till the butter melts; this mixture is immersed in inclined 
position in cow’s milk. This procedure is repeated for 30 time to get purified sulphur.  
Each time, fresh milk is to be used. 
 
2. Sittoduvai (Odukkan): 
 Wash with clean water, leaves and tender stems are crushed and juice is 
extracted. 
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PREPARATION PROCESS 
GANTHAGA PARPAM 
 Ganthagam is placed in stone morter and rubbed with sittoduvai juice for 
about 6 hours and made into cake.  Next grind collinus leaves made into paste 
Ganthagam is placed within the oduvan paste and dried, then it is sealed with 7 clay 
clothes and dried into sunlight. 
 This is placed under the coarse sand and subjected into incineration process by 
using 96 cow dung cakes.  After cooling ganthagam is taken again rubbed with 
Odukkan juice made into cake and dried.  Then the leaves are made into paste then 
ganthagam is placed within the paste and dried.  Then it is sealed with seven clay 
clothes and dried into sunlight. 
 This is again kept under coarse sand and subjected into incineration process by 
using 96 cowdung cakes.  After cooling ganthagam is taken this process is repeated 
for about 3 times, obtained ganthagam cake is placed in a stone mortor and make into 
fine powder and store in a glass container. 
 
Dosage :  
  488 mg (1 pannavedai) 
 
Adjuvants:  
  Cow’s ghee (or) Cow’s milk 
 
Shelf Life:  
  100 years 
 
Indications 
 Putru (Cancer), Kiranthi (Syphilis), Leprosy, Kandamaalai, Karappan, 
Soolai, Ooral, Pilavai. 
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INGREDIENTS OF GANDHAGA PARPAM 
GANDHAGAM 
PURIFIED GANDHAGAM 
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INGREDIENTS OF GANDHAGA PARPAM 
ODUKKAN 
ODUKKAN JUICE 
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PROCESS OF GANDHAGA PARPAM 
PREPARED DRUG 
KAVASAMIDUTHAL 
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 GANDHAGA PARPAM  PREPARATION 
PUDAMIDUTHAL 
GANDHAGA PARPAM  
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4.2.  STANDARDIZATION OF THE DRUG 
4.2.1.PHYSICAL STANDARDIZATION AS PER SIDDHA CLASSICAL 
LITERATURE: 
  Standardization of drug means confirmation of it’s quality and purity and 
detection of the nature of adulterant of various parameters like morphological, 
microscopic, physical, chemical and biological observations. 
1. Colour:  
  The finished form of Parpam is white colour (Except Thanga parpam – It is 
yellow in colour) 
2. Odour: 
  The finished form of Parpam is odourless ie, without any odour related to it’s 
ingredients. 
3. Taste: 
  A small amount of Parpam was kept in the tip of the tongue, which is 
tasteless. Properly prepared Parpam should be completely tasteless. If any taste 
present in Parpam, it indicates the preparation was not well prepared. It needs another 
pudam (incineration) process.  
4. Finger Print Test: 
  Well prepared Parpam should be very fine. A pinch of Parpam was taken and 
rubbed in between the thumb and index finger. It entered into the depressions and 
furrows of the fingers.It confirmes the fineness of Parpam. 
 5. Floating on Water:  
  A pinch of Parpam was sprinkled over the water in a glass container. The 
Parpam particles did not sink but floated on the water surface. It indicates the 
lightness of Parpam.  
6. Lustre: 
  If any glowing particles seen in the  Parpam , it shows that the drug is not 
prepared properly and possess unchanged substances like metals and other toxic 
substances. So, there should be no glowing particles present in the properly prepared 
Parpam. The Parpam was taken in a Petri dish and observed for any lustre in daylight 
via magnifying glass. 
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4.2.2. STANDARDIZATION OF TEST DRUG BY USING MODERN 
TECHNIQUES: 
  Standardization of drug helps to authenticate and determine its quality and 
efficiency. Thus, the process involves qualitative and quantitative analysis by means 
of physico – chemical properties and instrumental analysis. 
The physico – chemical analysis of GANDHAGA PARPAM has been done in iit Lab- 
chennai 
  The chemical finger prints are engaged by using modern analytical technique 
Fourier Transform Infra –Red Spectroscopy (FTIR) and Powder X-ray diffraction 
methods. 
  The particle size and qualitative analysis of chemical elements of 
GANDHAGA PARPAM are also assessed by Scanning Electron Microscope (SEM) 
and Inductively Coupled Plasma Optical Emission Spectroscopy (ICP-OES).  
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4.2.3. PHYSICO CHEMICAL STANDARDIZATION 
1. LOSS ON DRYING (INDIAN PHARMOCOEPIA, 1996) 
               Loss on drying is the loss in percentage w/w resulting from water and 
volatile matter of any kind that can be driven off under a specified condition. A glass 
stopper, shallow weighing bottle was weighed accurately and the quantity of the 
sample as specified was transferred to the bottle was weighed accurately and the 
quantity of the sample as specified was transferred to the bottle covered and weighed. 
The sample was distributed evenly and the bottle was placed in the drying chamber. 
The sample was then dried for a specific period of time, and the bottle was removed 
from the chamber and allowed to cool at room temperature in a desiccators before 
weighing. The normal range is between 6 – 8 %. 
 
2. TOTAL ASH: 
       Two grams of ground air dried powder of GANDHAGA PARPAM  was accurately 
weighed in a previously ignited and tared silica crucible. The drug was gradually 
ignited by raising the temperature to 450oC until it was white. The sample was cooled 
in a desiccators and weighed. The percentage of total ash was calculated with 
reference to air-dried drug. 
a)Acid insoluble ash 
              The ash was boiled with 25ml of 2M hydrochloric acid for 5 minutes, the 
insoluble matter was collected on an ash less filter paper, washed with hot water, 
ignited cooled in a desiccators, and weighed. The percentage of acid insoluble ash 
calculated with reference to the air-dried drug. 
b)Water soluble extractive 
               Proceed as directed for the determination of Alcohol-soluble extractive , 
using chloroform water instead of ethanol. 
c)Alcohol soluble extractive 
                Macerate 5g of the air dried drug, coarsely powdered, with 100 ml of 
alcohol of the specified strength in a closed flask for 24 hrs, shaking frequently during 
six hours and allowing to stand for eighteen hours. Filter rapidly, taking precautions 
against loss of solvent, evaporate 25 ml of the filtrate to dryness in a tared flat 
bottomed shallow dish, and dry at 105o to constant weight. Calculate the percentage 
of alcohol-soluble extractive with reference to the air-dried drug. 
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MICROBIAL LIMIT TEST OF GANDHAGA PARPAM 
Evaluation of Total Aerobic Bacterial Count 
1.1. Preparation of  Sample for Experimental Work 
  Weighed 10 gm of the homogenized drug sample aseptically and dissolved in 
10 ml of sterile water and made up to 100 ml with the sterile water. The insoluble 
drug product was suspended in 100 ml of buffered sodium chloride-peptone solution 
(pH 7.0).   
1.2. Serial dilution of Sample 
   A serial dilution is the dilution of a sample, in 10-fold dilutions. From the 
sample, 1 ml of the sample was added to 9 ml of sterile distilled water and mixed it 
well. This dilution was denoted as 10-1 dilution. From this dilution, 1ml was taken 
from that mixture is added to 9 ml, and designated as 10-2 dilution. The same 
procedure was repeated up to    10-4. 
1.3. Isolation of Total Viable Aerobic Microbial Count 
1.3.1. Isolation of Bacteria by Plate Count Method 
 In this test, the bacteria in sample were made to grow as colonies, by 
inoculating a known volume of sample into a solidifiable nutrient medium (Casein 
Soybean Digest agar or Nutrient agar medium) in petridish. The agar plate was 
prepared by mixing growth medium with agar and then sterilized by autoclaving. 
Once the agar was cooled to 45oC, approximately 15 to 20 ml of medium was poured 
into a sterile Petri dish under aseptic condition and left to solidify for 15 minutes. 
After solidification, each plate was smear with 0.1 ml of sample from the dilution of 
10-1 and 10-2. After inoculations, all the plates were incubated at 37oC for 24 hours. 
After incubation, the bacterial colonies were developed as visible to the naked eye and 
the number of colonies on a plate was counted using Quebec Colony Counter. Plates 
with an average of from 30 to 300 colonies of the target bacterium were selected for 
colony count. Because of the statistical problems, plates with lower than 30 colonies 
greater than 300 colonies were rejected     
 
1.3.1.1. Composition of Nutrient Agar Media 
Peptone  : 5.0 gm  
Sodium chloride : 5.0 gm  
Beef extract  : 1.5 gm 
Yeast extract  : 1.5 gm 
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Agar   : 15.0 gm 
Distilled water  : 1000 ml  
 pH ( at 25°C)  : 7.4±0.2 
 
1.3.2. Isolation of Fungi 
  From each of the above prepared samples, 0.1 ml of sample was transferred to 
Sabouraud Dextrose agar (SDA) prepared with Chloramphenicol. The plates were 
then incubated for 5 days at room temperature (20 to 25°C). After incubation, the 
fungal colonies were observed and calculated.   
 
1.3.2.1. Composition of SDA 
Dextrose   : 40 gm 
Peptone   : 10 gm 
Agar   : 15 gm 
Distilled water : 1000 ml 
 
1.4. Evaluation of Antimicrobial Activity of Drug 
  Antimicrobial activity was performed by agar well diffusion method on agar. 
 
1.4.1 Preparation of drug extracts solutions for the experiment  
  The dried drugs were weighed and dissolved in sterile distilled water to 
prepare appropriate dilution to get required concentrations of about 10, 20 and 
30µg/ml. They were kept under refrigerated condition unless they were used for the 
experiment. 
 
1.4.2. Procedure for the Agar Well Diffusion Test 
   The antibacterial screening of the drugs were carried out by determining the 
zone of inhibition using agar well diffusion method. All the drug extracts were tested 
against four pathogenic bacterial strains of gram positive and gram negative organism 
by agar well diffusion method. 
 
1.4.3. Bacterial Inoculums Preparation 
   Inoculums of Staphylococcus aureus, Escherichia coli, Klebsiella 
pneumoniae, Proteus vulgaris, and Bacillus substilis were prepared in nutrient broth 
medium and kept for incubation at 37°C for 8 hrs. 
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1.4.4. Agar well-diffusion method  
  This method was followed to determine the antimicrobial activity. Muller-
Hinton Agar media plates were swabbed (sterile cotton swabs) with 8 hour old - broth 
culture of respective bacteria. After inoculation, wells with the size of 10 mm 
diameter and about 2 cm a part were made in each of these plates using sterile cork 
borer. Stock solution of each drug extract was prepared at a concentration of 1 mg/ml 
in water. About 100 µl of different concentrations of drug solvent extracts were added 
into the wells and allowed to diffuse at room temperature for 2 hrs. The plates were 
incubated at 37°C for 24 hrs. After incubation, the diameter of the inhibition zone 
(mm) was measured and the activity index was also calculated.  
 
1.4.4.1. Composition of Muller Hinton Agar Media 
 Beef Extract     : 02.00 gm 
 Acid Hydrolysate of Casein   : 17.50 gm 
 Starch      : 01.50 gm 
 Agar     : 17.00 gm 
 
1.5. Evaluation of Specified Microorganisms  
1.5.1. Isolation & Identification of Escherichia coli 
  One ml of the prepared sample was added in a sterile screw-capped container 
containing 50 ml of nutrient broth and mixed well. Then, it was allowed to stand for 1 
hour and mixed well again. After one hour, the screw caps of the bottle was loosened 
and incubated at 37º for 18 to 24 hours. 
 
1.5.1.2. Primary Test 
  From the above prepared enrichment culture, 1.0 ml was taken and transferred 
aseptically into a tube containing 5 ml of Mac- Conkey broth. Inoculated tubes were 
incubated in a water-bath at 36º to 38º for 48 hours.  
 
1.5.1.3. Secondary Test 
  From the primary test, 1.0 ml of the enrichment culture was taken and 
transferred aseptically in to 5 ml of peptone water. It was then incubated in a water-
bath at 43.5º to 44.5º C for 24 hours and observed the tubes for acid and gas. Then, 
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the culture was subjected to biochemical tests of imvic and the results were observed 
and correlated.       
 
1.5.1.4. Alternative test  
  It was done by a loop full of enriched culture in the primary test was streaked 
on a sterile Mac-Conkey agar medium. Then, the plates were inverted and incubated 
at 37 º C for 24 hours. After incubation, the pink or brick red color colonies were 
examined and transfer them individually into the surface of Eosin Methylene Blue 
agar medium (EMB), on Petri dishes. Inoculated plates were inverted and incubated at 
37 º C for 24 hours. After incubation, the colonies on medium were checked for their 
color appearance like green metallic sheen under reflected light. The colonies were 
subjected to confirmation by further suitable cultural and biochemical tests. 
 
1.5.1.5. Components of Eosin Methylene Blue Agar Media 
Pancreatic digest of gelatin   : 10.0 g 
Dibasic potassium phosphate   : 2.0 g 
Lactose      : 10.0 g 
Eosin Y      : 400 mg 
Methylene blue    : 65 mg 
Agar       : 15.0 g 
Distilled water     : 1000 ml 
 
1.5.2. Isolation & Identification of Salmonella sp.  
  One ml of the prepared sample was added in a sterile screw-capped container 
containing 100 ml of nutrient broth and mixed well. Then, it was allowed to stand for 
1 hour and mixed well again. After one hour, the screw caps of the bottle was 
loosened and incubated at 37º for 18 to 24 hours. 
 
1.5.2.1. Primary Test  
  From the above prepared enrichment culture, 1.0 ml was taken and transferred 
aseptically into a tube containing 10 ml of Selenite F broth. Inoculated tubes were 
incubated in a water-bath at 36º to 38º for 48 hours. After incubation, the culture was 
subcultured on two of the agar media namely Bismuth sulphate agar and Deoxy 
cholate citrate agar and incubated the plates at 36º to 38º for 18 to 24 hours. After 
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incubation, colonies were observed on the medium and confirmed the genus 
Salmonella based on guidelines. 
 
1.5.2.2. Secondary test 
  The suspected colonies of the primary test were subcultured on the slant of 
triple sugar-iron agar in test tube and in urea broth. Both media were incubated at 
37ºC for 24 hours. After incubation, the results were observed according to the 
development of color change and acid / gas in media.  The presence of Salmonella 
was confirmed by agglutination tests. 
 
1.5.2.3. Composition of Salmonella Shigella Agar Media 
Beef Extract     : 5.0 gm 
Enzymatic Digest of Casein   : 2.5 g 
Enzymatic Digest of Animal Tissue  : 2.5 gm 
Lactose     : 10 gm 
Bile salts     : 8.5 gm 
Sodium Citrate     : 8.5 gm 
Ferric Citrate     : 1.0 gm 
Brilliant Green    : 0.00033 gm 
Neutral Red     : 0.025 
Agar      : 13.5 gm 
Distilled water     : 1000 ml 
  
1.5.3. Isolation and Identification of Pseudomonas aeruginosa  
  From the above prepared enrichment culture, 1.0 ml was taken and transferred 
aseptically into 100 ml of fluid soyabean-casein digest medium and mixed well.  The 
inoculated tubes were incubated at 37º C for 24 hours. After incubation, the growth of 
bacteria was checked. From this, a loop full of culture was streaked on the surface of 
Cetrimide agar medium and Pseudomonas Isolation Agar medium and incubated at 
incubated at 37º C for 24 hours. After incubation, the colonies from the agar surface 
of these two media were checked for detection of fluorescein and pyocyanin. 
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1.5.3.1. Composition of Cetrimide Agar Media 
Pancreatic digest of gelatin   : 20.0 g 
Magnesium chloride    : 1.4 g 
Potassium sulphate    : 10.0 g 
Cetrimide     : 0.3 g 
Agar      : 13.6 g 
Glycerin     : 10.0 g 
Distilled Water t   : 1000 ml 
 
1.5.4. Isolation and Identification of Staphylococcus aureus 
  From the above prepared enrichment culture, a loop full of culture was taken 
and transferred aseptically on Mannitol salt agar and incubated at 37º C for 24 hours.. 
After incubation, the colonies were subjected to confirmation by hem agglutination 
test.  
 
1.5.4.1. Composition of Mannitol Salt Agar Media 
Pancreatic digest of gelatin   : 5.0 g 
Peptic digest of animal tissue  : 5.0 g 
Beef extract     : 1.0 g 
D-Mannitol     : 10.0 g 
Sodium chloride    : 75.0 g 
Agar      : 15.0 g 
Phenol red     : 25 mg 
Distilled Water    : 1000 ml 
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4.2.4  BIO-CHEMICAL ANALYSIS 
PROCEDURE: 
  5gms of  the drug was wighted accurately and placed in a 250ml clean beaker. 
Then 50ml of distilled water is added and dissolved well. Then it is boilded well for 
about 10 minutes. It is cooled and filtered in a 100ml volumetric flask and then it is 
make up to 100ml with distilled water. This fluid is taken for analysis. 
 
QUALITATIVE ANALYSIS FOR BASIC RADICALS: 
Test for Calcium: 
 2ml of the above prepared extract is taken in a clean test tube. To this add 2ml 
of 4% Ammonium oxalate solution. Formation of white precipitate indicates the 
presence of calcium. 
Test for Iron (Ferric): 
 The extract is acidified with glacial acetic acid and potassium ferro cyanide. 
Formation of blue colour indicates the presence of ferric iron. 
Test for Iron (Ferrous): 
 The extract is treated with concentrated Nitric acid and ammonium thio-
cyanate solution. Formation of blood red colour indicates the presence of ferrous iron. 
Test for Zinc: 
 The extract is treated with potassium ferro-cyanide. Formation of white 
precipitate indicates the presence of zinc. 
 
QUALITATIVE ANALYSIS FOR ACIDIC RADICALS: 
Test for Sulphate: 
 2ml of extract is added to 5% barium chloride solution. Formation of white 
precipitate indicates the presence of sulphate. 
Test for Chloride: 
 The extract is treated with silver nitrate solution. Formation of white 
precipitate indicates the presence of chloride. 
Test for Phosphate: 
 The extract is treated with ammonium molybdate and concentrated nitric acid. 
Formation of yellow precipitate indicates the presence of phosphate. 
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Test for Carbonate: 
 On treating the extract with concentrated hydrochloric acid giving brisk 
effervescence indicates the presence of carbonate. 
Test for starch: 
 The extract is added with weak iodine solution. Formation of blue colour 
indicates the presence of starch. 
Test for albumin: 
 The extract is treated with Esbach`s reagent. Formation of yellow precipitate 
indicates the presence of albumin. 
Test for tannic acid: 
 The extract is treated with ferric chloride. Formation of bluish black 
precipitate indicates the presence of tannic acid. 
Test for unsaturation: 
 The extract is treated with potassium permanganate solution. The dis-
colourization of potassium permanganate indicates the presence of unsaturated 
compounds. 
Test for the reducing sugar: 
 5ml of Benedict`s qualitative solution is taken in a test tube and allowed to 
boil for 2 minutes and added 8-10 drops of the extract and again boil it for 2 minutes. 
Any colour change indicates the presence of reducing sugar. 
Test for amino acid: 
 One or two drops of the extract is placed on a filter paper and dried it well. 
After drying, 1% Ninhydrin is sprayed over the same and dried it well. Formation of 
violet colour indicates the presence of amino acid. 
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4.2.5. PHYTOCHEMICAL ANALYSIS OF GANDHAGA PARPAM 
Analysis of the siddha preparation GANDHAGA PARPAM 
  The siddha preparation GANDHAGA PARPAM was prepared and used for 
phytochemical analysis.  
  Preliminary test, on the siddha preparation GANDHAGA PARPAM was carried 
out for the presence of alkaloids, carbohydrates, glycosides, phytosterols, saponins, 
tannins, phenolic compounds, proteins and free amino acids, flavanoids, lignin, fixed 
oils and fats. The methods adopted for the estimation are as follows:  
1.Test for Alkaloids (Evans, 1997)  
A small segment of the siddha preparation GANDHAGA PARPAM was mixed 
separately with a few drops of dilute hydrochloric acid and filtered. The filtrates were 
tested carefully with various alkaloidal reagents as follows:  
a) Mayer’s test (Evans, 1997): 
  To a few ml of filtrate, a drop of Mayer’s reagent is added by the side of the 
test tube. A white or creamy precipitate indicates that the test as positive.  
b) Hager’s test (Wagner et al., 1996): 
    To a few ml of filtrate, one to 2ml of Hager’s reagent is added. A prominent 
yellow precipitate indicates the test as positive.  
c) Dragendorff’s test (Waldi, 1965):  
  To a few ml of filtrate, one to 2ml of Dragendorff’s reagent is added. A 
prominent yellow precipitate indicates the test as positive.  
 
2.Test for Carbohydrates (Ramakrishnan et al., 1994)  
  A small quantity of siddha preparation GANDHAGA PARPAM was dissolved 
separately in 5ml of distilled water and filtered. The filtrate was subjected to 
Molisch’s test to detect the presence of carbohydrates. Filtrate was treated with 2-3 
drops of 1% alcoholic alpha naphthol solution and 2ml of concentrated sulphuric acid 
was added along the sides of the test tube. Appearance of brown ring at the junction 
of 2 layers shows the presence of carbohydrates.   
 
3.Test for Glycosides  
  The siddha preparation GANDHAGA PARPAM was hydrolyzed with 
hydrochloric acid for few h on a water bath and the hydrolysate was subjected to 
Legal’s and Borntrager’s test to detect the presence of different glycosides.  
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(a) Legal’s Test: 
   To the hydrolysate, one ml of pyridine and few drops of sodium nitro prusside 
solution were added and then it was made alkaline with sodium hydroxide solution. 
Appearance of pink to red color shows the presence of glycosides and aglycones.  
(b) Borntrager’s Test:  
                  Hydrolysate was treated with chloroform and the chloroform layer was 
separated. To this equal quantity of dilute ammonia solution was added. Ammoniacal 
layer acquires pink color, shows the presence of glycosides (Evans, 1997).  
 
4.Test for Phytosterols (Finar, 1986)  
(a) Liebermann Burchard Test:  
               Small amount of the siddha preparation GANDHAGA PARPAM was 
dissolved with 3ml of acetic anhydride, a few drops of glacial acetic acid and 
followed by the addition of few drops of concentrated sulphuric acid. Appearance of 
bluish green color shows the presence of phytosterols.  
(b) Salkowski Test:  
               Small quantities of the siddha preparation GANDHAGA PARPAM were 
dissolved in chloroform separately. This chloroform solution was added with few 
drops of concentrated sulphuric acid. The appearance of bluish green color shows the 
presence of phytosterols.  
 
5.Test for Saponins (Kokate, 1999)  
Frothing Test:  
  The siddha preparation GANDHAGA PARPAM was diluted separately with 
20ml of distilled water and it was agitated on a graduated cylinder for 15min. 
Absence of the foam formation shows the devoid of saponins 
 
6.Test for Phenolic Compounds and Tannins (Mace, 1963)  
  Small quantities of siddha preparation GANDHAGA PARPAM was dissolved 
separately in water and tested for the presence of phenolic compound and tannins. In 
the process of testing and treating, the following observations were noted:  
a) Dilute ferric chloride solution (5%) gives a dark green color. 38  
b) 10% aqueous potassium dichromate solution gives yellowish brown 
precipitate.  
c) 10% lead acetate solution gives a white precipitate.  
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  7.  Test for Proteins and Free Amino Acids (Fisher, 1968; Ruthmann, 1970)  
  Small quantities of various siddha preparation GANDHAGA PARPAM was 
dissolved in few ml of water and the following reaction were carried out  
(a) Millon’s Test :  
               To 2ml of filtrate, few drops of Millon’s reagent were added. A white 
precipitate indicates the presence of proteins (Rasch and Swift, 1960).  
(b) Ninhydrin Test:  
               To 2ml of filtrate 2 drops of ninhydrin solution was added. A characteristic 
purple color indicates the presence of amino acids (Yasma and Ichikawa, 1953).  
(c) Biuret Test:  
                An aliquot of 2ml of filtrate was treated with a drop of 2% copper sulphate 
solution. To this, 1ml of ethanol (95%) was added, followed by excess of potassium 
hydroxide pellets, Pink color in the ethanol layer indicates the presence of protein 
(Gahan, 1984).  
 
8.Test for Flavanoids  
(a) Shinoda’s Test:  
   Small quantity of siddha preparation GANDHAGA PARPAM was treated with 
alcohol to that a piece of magnesium was added followed by an addition of 
concentrated hydrochloric acid drop wise and heated. Appearance of magenta color 
shows the presence of flavanoids (Harborne, 1984).  
(b) Florescence Test:  
   Small quantity of GANDHAGA PARPAM was dissolved separately in alcohol 
and a drop of that extract was placed on Whatman filter paper and observed under UV 
light. Florescence indicates the presence of flavanoids.  
 
9. Tests for Lignin  
           Small quantities of GANDHAGA PARPAM was dissolved separately in few ml 
of alcoholic solution of hydrochloric acid and phloroglucinol gives red color, which 
shows lignin is present.  
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10. Tests for Fixed oils and Fats  
(a) Spot Test: 
             A small quantity of siddha preparation GANDHAGA PARPAM was placed 
between 2 filter papers. Oil stains produced with any extract shows the presence of 
fats and fixed oils in the GANDHAGA PARPAM (Harborne, 1984).  
 
(b) Saponification Test:  
                 A small quantity of siddha preparation GANDHAGA PARPAM was treated 
with few drops of 0.5N alcoholic potassium hydroxide along with 2 to 3 drops of 
phenolphthalein. Later the mixture is refluxed for about 2h. Soap formation indicates 
the presence of fats and fixed oils in the GANDHAGA PARPAM. 
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4.2.6.  INSTRUMENTAL ANALYSIS 
SCANNING ELECTRON MICROSCOPE (SEM) 
 
Fig. No. 1   Scanning Electron Microscope (SEM) 
 
  The microstructure of the powders was examined using a Hitachi S 3000H 
scanning electron microscope  
Introduction: 
  The scanning Electron Microscope is one of the most versatile instruments 
available for the examination and analysis of the micro structural characteristics of 
solid objects. The primary reason for the SEM’s usefulness is the high resolution 
which can be obtained when bulk objects are examined; values of the order of 5nm 
(50degreeA) are usually quoted for commercial instruments. Advanced research 
instruments have been described which have achieved resolutions of about 2.5nm (25 
degree A). Any solid material can be studied. Sample size is limited to specimens less 
than about 10µm in diameter 
 
Principle:  
  The beam is then rastered over the specimen in synchronism with the beam of 
a cathode ray tube display screen. The eleastically scattered secondary electrons are 
emitted from the sample surface and collected by a scintillator, the signal from which 
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is used to modulate the brightness of the cathode ray tube. In this way the secondary 
electron emission from the sample is used to form an image on the CRT display 
screen. (Goldstein, et. al., 1992) 
 
SEM MECHANISM 
Procedure: 
  An electron beam passing through an evacuated column is focused by 
electromagnetic lenses onto the specimen surface. Since an electron is a charged 
particle, it has a strong interaction with the specimen (due to coulomb interaction).So 
when an electron beam images on a specimen, it is scattered by atomic layers near the 
surface of the specimen. As a result, the direction of electron motion changes and its 
energy is partially lost. Once an incident electron (primary electron) enters a 
substance, its direction of motion is influenced by various obstructions (multiple 
scattering), and follows a complicated trajectory which is far from a straight line. 
Also, when electrons with the same energy are incident on the specimen surface, a 
portion of electrons is reflected in the opposite direction (back scattered) and the 
remainder is absorbed by the specimen (exciting X- rays or other quanta in the 
process). If the specimen issufficiently thin, the electron can pass all the way through 
the specimen (transmitted electrons, scattered or non-scattered). 
  The depth at which various signals are generated due to electron beam – 
specimen interaction indicates the diffusion area of the signals in the specimen in 
addition to the local chemistry of the specimen. Secondary electrons mainly indicate 
information about the surface of a specimen. Since secondary electrons do not diffuse 
much inside the specimen, they are most suitable for observing the fine-structures of 
the specimen surface. That is to say, sharp scanning images with high resolution can 
be expected from secondary electrons, because of the smaller influence on resolution 
by their diffusion.  
  As the incident electron energy increases, the probability of incident electrons 
Colliding with elemental components of the specimen and releasing secondary 
electrons also increases. In other words, as the incident energy increases, the emission 
of electrons from the specimen also increases. However, as the energy increases 
beyond a certain level, the incident electrons penetrate deeper into the specimen with 
the result that the specimen derived electrons use up most of their energy to reach the 
specimen surface. Consequently, the electron emission yield decreases. Therefore, the 
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peak secondary electron emission yield occurs at a specific entry level of the incident 
electrons. 
  In order to verify the existence of a substance and recognize its shape, the 
image contrast must be well defined. In other words, even if a system boasts 
extremely high resolution, if image contrast is poor, it would be extremely difficult to 
determine the existence of a substance, let alone recognize its shape. Another 
important feature of the SEM is the three-dimensional appearance of the specimen 
image, which is a direct result of the large depth of field.  
 
Applications: 
  The SEM is capable of examining objects at very low magnification. This 
feature is useful in viewing particle size and shape of any composition at various 
stages of preparation in Siddha system as well as other fields.The large depth of field 
available in the SEM makes it possible to observe 3-dimensional objects in stereo. 
Today, a majority of SEM facilities are equipped with X-ray analytical capabilities. 
Thus topographic crystallographic and compositional information can be obtained 
rapidly, efficiently and simultaneously from the same area. 
  The author was chosen this analysis for detecting Particle size of the classical 
Siddha herbo-mineral drug GANDHAGA PARPAM. SEM results of GANDHAGA 
PARPAM were represented in results section. 
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Fig. No. 2 FOURIER TRANSFORM-INFRA RED SPECTROSCOPY 
(FT-IR) 
 
 
Introduction: 
  Vibrational spectroscopy is an extremely useful tool in the elucidations of 
molecular structure .The spectral bands can be assigned to different vibrational modes 
of the molecule. The various functional groups present in the molecule can be 
assigned by a comparison of the spectra with characteristic functional group 
frequencies. As the positions of the bands are directly related to the strength of the 
chemical bond, a large number of investigations including intermolecular interactions, 
phase transitions and chemical kinetics can be carried out using this branch of 
spectroscopy. In IR spectroscopy, the resonance absorption is made possible by the 
change in dipole moment accompanying the vibrational transition. The Infrared 
spectrum originates from the vibrational motion of the molecule. The vibrational 
frequencies are a kind of fingerprint of the compounds. This property is used for 
characterization of organic, inorganic and biological compounds. The band intensities 
are proportional to the concentration of the compound and hence qualitative 
estimations are possible. The IR spectroscopy is carried out by using Fourier 
transform technique.  
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Principle: 
  Infra red spectroscopy involves study of the interaction of electromagnetic 
radiation with matter. Due to this interaction, electromagnetic radiation characteristic 
of the interacting system may be absorbed (or emitted). The experimental data consist 
of the nature (frequency of wave length) and the amount (intensity) of the 
characteristic radiation absorbed or emitted. These data are correlated with the 
molecular and electronic structure of the substance and with intra- and inter molecular 
interactions. 
Source   : Nernst Glower 
Beam splitter  :  It is made up of a transparent material. Thin  
films of  Silicondepositedon  Potassium bromide  
(KBr) Bromide (KBr) Detectors:  DeutratedTriGlycine Sulphate (DTGS). 
Scan Range  :  MIR 450to 4000 cm-1 
Resolution  :   4.0 cm-1 
Sample required : 50mg, solid or liquid 
Sampling Techniques: There are a variety of techniques for sample  
preparation physical form of the sample to be  
analyzed. 
Solid   : KBr or Nujol mull method. 
Liquid   : Csl / TIBr Cells 
Gas   : Gas cells 
 
Measurements Techniques: 
The procedure for recording the %T or %A is as follows: 
1) Air is first scanned for the reference and stored. The sample is then recorded 
and finally the ratio of the sample and reference data is computed to give 
required  % T  or % A at various frequencies. 
2) Study of substances with strong absorbance bands and weak absorbance bands 
aswell as possible. 
3) Small amount of samples are sufficient 
4) High resolution is obtained. 
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Procedure: 
  Typically,1.5 mg of protein, dissolved in the buffer used for its purification, 
were centrifuged in a 30 K Centric on micro concentrator (Amicon) at 3000_g at 4oC 
until a volume of approximately 40 Al. 
1) Then, 300 Al of 20 mM buffer, prepared in H20 or 2H20, pH or p2H 7.2, were 
added and the sample concentrated again. The p2H value corresponds to the 
pH meter reading + 0.4. The concentration and dilution procedure was 
repeated several times in order to completely replace the original buffer with 
the This buffer. 
2) The washings took 24 h, which is the time of contact of the protein with the 
2H20medium prior FT-IR analysis. In the last washing, the protein was 
concentrated to fine a volume of approximately 40 Al and used for the infrared 
measurements.The concentrated protein sample was placed in CaF2 windows 
and a 6 Am tin spacer or a 25 Am Teflon spacer for the experiments in H20 or 
2H20, respectively. FT-IR spectra were recorded by means of a Perkin-Elmer 
-Spectrum-1 FT-IR spectrometer using a deuterated triglycinesulfate detector. 
3) At least 24 h before, and during data acquisition, the spectrometer were 
continuously purged with dry air at a dew point of 40oC. Spectra of buffers 
and samples were acquired at 2 cm_1 resolution under the same scanning and 
temperature conditions. In the thermal denaturation experiments, the 
temperature was raised in 5oC steps from 20 to 95oC. 
4) Before spectrum acquisition, samples were maintained at the desired 
temperature for the time necessary for the stabilization of temperature inside 
the cell (6 min).Spectra were collected and processed using the SPECTRUM 
software from Perkin-Elmer. Correct subtraction of H20 was judged to yield an 
approximately flat baseline at 1900-1400 cm_ 1, and subtraction of 2H20 was 
adjusted to the removal of the2H20 bending absorption close to 1220 cm_ 1 
KBr Method 
1) The sample is grounded using an agate mortar and pestle to give a very fine 
powder. 
2) The finely powder sample is then mixed with about 100mg dried KBr salt. 
3) The mixture is then pressed under hydraulic press using a die to yield a 
transparent disc and measure about 13mm diameter and 0.3mm in thickness. 
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Nujol Mull Method: 
1) The sample is ground using an agate mortar and pestle to give a very fine 
powder. 
2) A small amount is then mixed with nujol oil to give a paste and this paste is 
thenapplied between two sodium chloride plates. 
3) The plates are then placed in the instrument sample holder ready for scanning. 
Liquids: 
1) Viscous liquids can be smeared in the cell and directly measured. 
2) For dilute solutions, liquid cells and variable path length cells are employed. 
Applications: 
   Infrared spectrum is useful in identifying the functional groups like -OH, -
CN, -CO, -CH, -NH2, etc. Also quantitative estimation is possible in certain cases for 
chemicals, pharmaceuticals, petroleum products, etc. Resins from industries, water 
and rubber samples can be analyzed.  
 
 
 
Fig. No. 3 Mechanism of FTIR analyzer 
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Analytical Capabilities: 
1) Identifies chemical bond functional groups by the absorption of infrared 
radiation which excites vibrational modes in the bond. 
2) Especially capable of identifying the chemical bonds of organic materials  
3) Detects and identifies organic contaminants. 
4) Identifies water, phosphates, sulphates, nitrates, nitrites, and ammonium ions  
5) Detection limits vary greatly, but are sometimes <1013 bonds/cm3 or 
sometimes sub monolayer .Useful with solids, liquids, or gases. 
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Fig. No. 4  INDUCTIVELY COUPLED PLASMA OPTICAL EMISSION 
SPECTROMETRY(ICP-OES): 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction: 
  Inductively coupled plasma optical emission spectrometry (ICP-OES) is an 
analytical technique used for the detection of trace metals. It is a type of emission 
spectroscopy that uses the inductively coupled plasma to produce excited atoms and 
ions that emit electromagnetic radiation at wavelengths characteristic of a particular 
element. The intensity of this emission is indicative of the concentration of the 
element within the sample. 
 
Mechanism: 
  The ICP-OES is composed of two parts:  ICP and the optical spectrometer. 
The ICP torch consists of 3 concentric quartz glass tubes. The output or “work” coil 
of the radiofrequency (RF) generator surrounds part of this quartz torch. Argon gas is 
typically used to create the plasma. 
  When the torch is turned on, an intense electromagnetic field is created within 
the coil by the high power radio frequency signal flowing in the coil. This RF signal is 
created by the RF generator which is, effectively, a high power radio transmitter 
driving the “workcoil” the same way a typical radio transmitter drives a transmitting 
antenna. The argon gas flowing through the torch is ignited with a Tesla unit that 
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creates a brief discharge are through the argon flow to initiate the ionization process. 
Once the plasma is “ignited”, the Tesla unit is turned off. 
  The argon gas is ionized in the intense electromagnetic field and flows in a 
particular rotationally symmetrical pattern towards the magnetic field of the RF coil. 
Stable, high temperature plasma of about 7000 K is then generated as the result of the 
inelastic collisions created between the neutral argon atoms and the charged particles.  
A peristaltic pump delivers an aqueous or organic sample into a nebulizer where it is 
changed into mist and introduced directly inside the plasma flame. The sample 
immediately collides with the electrons and charged ions in the plasma and is itself 
broken down into charged ions. The various molecules break up into their respective 
atoms which then lose electrons and recombine repeatedly in the plasma, giving off 
radiation at the characteristic wavelengths of the elements involved. 
  Within the optical chamber(s), after the light is separated into its different 
wavelengths (colours), the light intensity is measured with a photomultiplier tube or 
tubes physically positioned to “view” the specific wavelength(s) for each element line 
involved, or, in more modern units, the separated colours fall upon an array of 
semiconductor photo detectors such as charge coupled devices (CCDs). In units using 
these detector arrays, the intensities of all wavelengths (within the system’s range) 
can be measured simultaneously, allowing the instrument to analyse for every element 
to which the unit is sensitive all at once. Thus, samples can be analysed very quickly. 
The intensity of each line is then compared to previously measured intensities 
ofknown concentrations of the elements and their concentrations are then computed 
by interpolation along the calibration lines. In addition, special software generally 
corrects for interferences caused by the presence of different elements within a given 
sample matrix.  
 
Applications : 
  ICP-OES is used in   the determination of metals, arsenic present in 
Traditional medicines, and trace elements bound to proteins. ICP-OES is widely used 
in minerals processing to provide the data on grades of various streams, for the 
construction of mass balances. 
  The author used it for elemental identification and quantitative compositional 
information of the GANDHAGA PARPAM . 
 
  
   72 PRE CLINICAL  STUDY OF  GANDHAGA PARPAM 
 
X-RAY POWDER DIFFRACTION 
(XRD) INSTRUMENTATION 
 X-ray diffractometers consist of three basic elements: an X-ray tube, a sample 
holder and an X-ray detector. 
 
 
Fig.No. 5 Bruker’s X-ray Diffraction D8-Discover instrument. 
 X-rays are generated in a cathode ray tube by heating a filament to produce 
electrons, accelerating the electrons towards a target by applying a voltage and 
bombarding the target material with electrons. When electrons have sufficient energy 
to dislodge inner shell electrons of the target material, characteristic X-ray spectra are 
produced. These spectra consist of several components, the most common being Kα 
and Kβ. Kα consists in part of Kα1 and Kα2. Kα1 has a slightly shorter wavelength and 
twice the intensity of Kα2. The specific wavelengths are characteristic of the target 
material (Cu, Fe, Mo, Cr). Filtering, by foils or crystal monochrometers, is required to 
produce monochromatic X-rays needed for diffraction. Kα1 and Kα2 are sufficiently 
close in wavelength such that a weighted average of the two is used. Copper is the 
most common target material for single-crystal diffraction, with CuKα radiation = 
1.5148A0. These X-rays are collimated and directed onto the sample. As the sample 
and detector are rotated, the intensity of the reflected X-rays is recorded. When the 
geometry of the incident X-rays impinging the sample satisfies the Bragg Equation, 
constructive interference occurs and a peak in intensity occurs. A detector records and 
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processes this X-ray signal and converts the signal to a count rate which is then output 
to a device such as a printer or computer monitor. 
The geometry of an X-ray diffractometer is such that the sample rotates in the path of 
the collimated X-ray beam at an angle θ while the X-ray detector is mounted on an 
arm to collect the diffracted X-rays and rotates at an angle of 2θ. The instrument used 
to maintain the angle and rotate the sample is termed a goniometer. For typical 
powder patterns, data is collected at 2θ from -50 to 700, angles that are present in the 
X-ray scan. 
Applications: 
 X-ray powder diffraction is most widely used for the identification of 
unknown crystalline materials (e.g. minerals, inorganic compounds). Determination of 
unknown solids is critical to studies in geology, environmental science, material 
science, engineering and biology. 
 
Other applications include: 
1) Characterization of crystalline materials 
2) Identification of the fine-grained minerals such as clays and mixed layer clays 
that are difficult to determine optically. 
3) Determination of unit cell dimensions. 
4) Measurement of sample purity. 
 
With specialized techniques, XRD can be used to: 
1) Determine crystal structures using Rietveld refinement 
2) Determine of modal amounts of minerals (quantitative analysis) 
3) Make textural measurements such as the orientation of grains in a 
polycrystalline sample. 
Strengths and Limitations of X-ray Powder Diffraction: 
Strengths: 
1) Powerful and rapid (<20 min) technique for identification of an unknown 
minerals. 
2) In most cases, it provides an unambiguous mineral determination. 
3) Minimal sample preparation is required. 
4) XRD units are widely available. 
5) Data interpretation is relatively straight forward. 
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Limitations: 
1) Homogenous and single phase material is best for identification of an 
unknown 
2) Must have access to a standard reference file of inorganic compounds (d-
spacings, hkls) 
3) Requires tenths of a gram of material which must be ground into a powder. 
4) Foe mixed materials, detection limit is -2% of sample. 
5) For unit cell determinations, indexing of patterns for non-isometric crystal 
systems is complicated. 
6) Peak overlay may occur and worsens for high angle ‘reflections’. 
User’s Guide-Sample Collection and Preparation: 
Determination of an unknown requires: the material, an instrument for grinding and 
a sample holder. 
1. Obtain a few tenths of a gram (or more) of the material, as pure as possible. 
2. Grind the sample to a fine powder, typically in a fluid to minimize inducing 
extra strain (surface energy) that can offset peak positions, and to randomize 
orientation. 
i. Powder less than -10 µm (or 200-mesh) in size is preferred. 
2. Place into a sample holder or onto the sample surface. 
i. Packing of the fine powder into a sample holder. Smear 
uniformly onto a glass slide, assuring a flat upper surface. 
3. Pack into a sample container 
4. Sprinkle on double sticky tape 
i. Typically the substance is amorphous to avoid interference 
5. Care must be taken to create a flat upper surface and to achieve a random 
distribution of lattice orientations unless creating an oriented smear. 
6. For unit cell determinations, a small amount of a standard with known peak 
positions (that do not interfere with the sample) can be added and used to 
correct peak positions. 
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Data Collection, Results and Presentation: 
Data collection: 
  The intensity of diffracted X-rays is continuously recorded as the sample and 
detector rotate through their respective angles. A peak in intensity occurs when the 
mineral contains lattice planes with d-spacings appropriate to diffract X-rays at that 
value of θ. Although each peak consists of two separate reflections (Kα1 and Kα2), at 
small values of 2θ the peak locations overlap with Kα2 appearing as a hump on the 
side of Kα1. Greater separation occurs at higher values of θ. Typically these combined 
peaks are treated as one. The 2λ position of the diffraction peak is typically measured 
as the center of the peak at 80% peak height. 
Data reduction: 
  Results are commonly presented as peak positions at 2θ and X-ray counts 
(intensity) in the form of a table or an x-y plot (shown above). Intensity (I) is either 
reported as peak height intensity, that intensity above background, or as integrated 
intensity, the area under the peak. The relative intensity is recorded as the ratio of the 
peak intensity to that of the most intense peak (relative intensity =I/I1 x 100). 
The d-spacing of each peak is then obtained by solution of the Bragg equation for the 
appropriate value of λ. Once all d-spacings have been determined, automated 
search/match routines compare the ds of the unknown to those of known materials. 
Because each mineral has a unique set of d-spacings, matching these d-spacings 
provides an identification of the unknown sample. A systematic procedure is used by 
ordering the d-spacings in terms of their intensity beginning with the most intense 
peak. Files of d-spacings for hundreds of thousands of inorganic compounds are 
available from the International Centre for Diffraction Data as the Powder Diffraction 
File (PDF). Many other sites contain d-spacings of minerals such as the American 
Mineralogist Crystal Structure Database. Commonly this information is an integral 
portion of the software that comes with the instrumentation. 
  The author used it for elemental identification and quantitative compositional 
information of the GANDHAGA PARPAM. 
 
  
  
   76 PRE CLINICAL  STUDY OF  GANDHAGA PARPAM 
 
4.3. TOXICOLOGICAL STUDIES 
4.3.1. ACUTE TOXICITY STUDY IN FEMALE WISTER RATS TO 
EVALUATE TOXICITY PROFILE OF GANDHAGA PARPAM 
OBJECTIVES 
  The aim of this Study is to evaluate the toxicity of the test substance 
GANDHAGA PARPAM , when administered orally to Female Wister Rats with 
different doses, so as to provide a rational base for the evaluation of the toxicological 
risk to man and indicate potential target organs. 
 
Guidelines followed: 
  (a)  OECD Guidelines No. 423, 
 
Study Design and Controls: 
1. Female Wister Rats in controlled age and body weight were selected. 
2. GANDHAGA PARPAM  was administered at 5 mg/kg, 50 mg/kg,  300 
mg/kg,1000  mg/kg, 2000  mg/kg,  body weight as  (Water) as suspension 
along with blank. 
3. The results were recorded on day 0, with single oral dosing period of 14 
days.  
EXPERIMENTAL PROCEDURE 
1. ANIMALS  
Supply 
        A total of 15 Female Wister Rats with an approximate age of 6 weeks and 
purchased from Central Animal House, Arulmigu Kalasalingam college of pharmacy, 
krishnankoil. On their arrival a sample of animals was chosen at random and weighed 
to ensure compliance with the age requested. The mean weights of Female Wister 
Rats were 100-150 g respectively.  The animals were housed in metabolic cages (55 x 
32.7 x 19 cm), with sawdust litter, in such a way that each cage contained a maximum 
of 3 animals of the same sex. 
  All animals underwent a period of 20 days of observation and acclimatization 
between the date of arrival and the start of treatment. During the course of this period, 
the animals were inspected by a veterinary surgeon to ensure that they fulfilled the 
health requirements necessary for initiation of the Study. 
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Housing 
  The Female Wister Rats were housed in metabolic cages (55 x 32.7 x 19 cm), 
placed on racks. From the week before initiation of the treatment, each cage contained 
a maximum of 3 rats of the same sex and treatment group. 
  Each cage was identified by a card, color coded according to the dose level. 
This card stated the cage number, number and sex of the animals it contained, Study 
number, test substance code, administration route, dose level and Study Director's 
name, date of the arrival of the animals and initiation of treatment. 
  The temperature and relative humidity were continuously monitored. Lighting 
was controlled to supply 12 hours of light (7:00 to 19:00 hours) and 12 hours of dark 
for each 24-hour period. 
  The cages corresponding to each experimental group were distributed on racks 
in such a manner that external factors, such as environmental conditions, were 
balanced as far as possible. 
2. DIET 
     All the rats had free access to a pelleted rat diet. The diet was analyzed by the   
manufacturer to check its composition and to detect possible contaminants. 
Water 
  The water was offered ad libitum in bottles.  
3. ADMINISTRATION ROUTE AND PROCEDURE 
          The test substance was administered orally. The Female Wister Rats belonging 
to the control group were treated with the vehicle (Water) at the same administration 
volume as the rest of the treatment groups. 
 The animals were marked on body with picric acid solution prepared in water. 
The marking within the cage was as below. 
Table – 1  Numbering and Identification 
Group No Animal Marking 
1 Head 
2 Body 
3 Tail 
 
 The group no., cage no., sex of the animal and animal no. were identified as 
indicated below using cage label and body marking on the animals 
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Cage No Group No Animal Marking Sex 
1 I H,B,T Female 
2 II H,B,T Female 
3 III H,B,T Female 
4 IV H,B,T Female 
5 V H,B,T Female 
 
Doses 
  The doses for the study were selected based on literature search and range 
finding study. Following the period of fasting, the animals were weighed and then 
drug was administered orally as single dose using a needle fitted onto a disposable 
syringe of approximate size at the following different doses. 
 
GROUP DOSE 
Group-I 5  mg/kg 
Group-II 50  mg/kg 
Group-III 300 mg/kg 
Group-IV 1000  mg/kg 
Group-V 2000 mg/kg 
 
  The test item was administered as single dose. After single dose administration 
period, all animals were observed for day 14. 
Dose Preparation 
  GANDHAGA PARPAM  was added in distilled water and completely 
dissolved to form oral for administration. The dose was prepared of a required 
concentration before dosing by dissolving, in distilled water. It was mixed well. The 
preparation for different doses was vary in concentrations to allow a constant dosage 
volume. 
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Administration 
  The test item was administered orally to each Female Wister rats as single 
dose using a needle fitted onto a disposable syringe of appropriate size at the 
following different doses. The concentration was adjusted according to its body 
weight. The volume was not exceeding 10 ml/kg bodyweight. Variability in test 
volume was minimized by adjusting the concentration to ensure a constant volume at 
all dose levels. 
Observation period 
  All animals were observed for any abnormal clinical signs and behavioral 
changes. The appearance, change and disappearance of these clinical signs, if any, 
were recorded for approximately 1.0, 3.0 and 4.0 hours post-dose on day of dosing 
and once daily thereafter for14 days. Animals in pain or showing severe signs of 
distress were humanely killed. The cageside observation was included changes in 
skin, fur, eyes and mucous membranes, occurrence of secretions and excretions. 
Autonomic activity like lacrimation,  piloerection, pupil size and unusual respiratory 
pattern, changes in gait, posture, response to handling, presence of clonic or tonic 
movements, stereotypes like excessive grooming and repetitive circling or bizarre 
behavior like self-mutilation, walking backwards etc were observed. At the 14th day, 
sensory reactivity to stimuli of different types (e.g. auditory, visual and proprioceptive 
stimuli) was conducted. Auditory stimuli responses were measured by clicker sound 
from approximately 30 cm to the rats; visual stimuli response were measured with the 
help of shining pen light in the eye of rats and placing a blunt object near to the eye of 
rats. Response to proprioceptive stimuli was measured by placing anterior/dorsal 
surface of animals paw to the table edge. The responses of reactions for these three 
exercises were normal in animals belonging to both the controls as well as drug 
treatment dose groups. 
Mortality and Morbidity 
  All animals were observed daily once for mortality and morbidity at 
approximately 1.0, 3.0 and 4.0 hours post dose on day of dosing and twice daily 
(morning and afternoon) thereafter for 14 days. 
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4.3.2. SUB-ACUTE TOXICITY STUDY IN WISTER RATS TO EVALUATE 
TOXICITY PROFILE OF GANDHAGA PARPAM     
                              
Objective 
  The objective of this ‘Sub-Acute Toxicity Study of  GANDHAGA PARPAM 
on Wister Rats’ was to assess the toxicological profile of the test item when treated 
as a single dose. Animals should be observed for 28 days after the drug 
administration. This study provides information on the possible health hazards likely 
to arise from exposure over a relatively limited period of time.  
Test Guideline Followed 
      OECD 407 Method - Sub-Acute Toxic Class Method (Repeated Dose 28-Day 
Oral Toxicity Study in Rodents) 
Test Item Detail 
  GANDHAGA PARPAM  
Test System Detail 
  The study was conducted on 5 male 5 female Wister rats. These   animals were 
selected because of the recommended rodent species for oral studies as per followed 
guideline and availability of Animals 8-12 weeks old male and female rats were 
selected after physical and behavioral examination. The body weight range was fallen 
within ± 20% of the mean body weight at the time of Randomization and grouping. 
The rats were housed in standard laboratory condition in Polypropylene cages, 
provided with food and water adlibitum in the Animal at Central Animal House, 
Arulmigu Kalasalingam College of Pharmacy, Krishnankoil. The experimental 
protocol was approved by Institutional Animal Ethical Committee as per the guidance 
of Committee for the Purpose of Control and Supervision of Experiments on Animals 
(CPCSEA), Ministry of Environment and Forest, government of India. 
Acclimatization 
   The animals were selected after veterinary examination by the veterinarian. 
All the selected animals were kept under acclimatization for a week. 
Randomization & grouping 
  One day before the initiation of treatment (days 0- last day of acclimatization), 
the selected animals were randomly grouped into three different groups containing 
minimum 5 male and 5 male animals per group.  
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The animals were marked on body with picric acid solution prepared in water. The 
marking within the cage was as below.   
Table – 2 Numbering and Identification 
  The group  no., cage no., sex of the animal and animal no. were identified  as 
indicated below  using cage  label and body marking on the animals: 
 
Case 
No 
Group No Animal Marking Sex 
1 CONTROL 
H,B,T,HB,NM 
H,B,T,HB, NM 
Male 
Female 
2 
Low dose of  GANDHAGA 
PARPAM 300mg/kg 
H,B,T,HB,NM 
H,B,T,HB, NM 
Male 
Female 
3 
Middle dose of GANDHAGA 
PARPAM 600mg/kg 
H,B,T,HB,NM                   
H,B,T,HB, NM 
Male 
Female 
4 
High dose of  GANDHAGA 
PARPAM 900 mg/kg 
H,B,T,HB,NM 
H,B,T,HB ,NM 
Male 
Female 
 
Husbandry 
Housing 
   The Wister rats were housed in standard polypropylene cages with stainless 
steel top grill. Paddy husk was used as bedding. The paddy husk was changed at least 
twice in a week. From the week before initiation of the treatment, each cage contained 
a maximum of 5 rats of the same sex and treatment group. 
Case 
No 
Group No Animal Marking 
1 CONTROL 
H,B,T,HB,NM   (Male)               
H,B,T,HB, NM (Female 
2 
Low dose of  GANDHAGA PARPAM 
300mg/kg 
H,B,T,HB,NM  (Male)                  
H,B,T,HB, NM (Female) 
3 
Middle dose of GANDHAGA 
PARPAM 600mg/kg 
H,B,T,HB,NM  (Male)                  
H,B,T,HB, NM (Female) 
4 
High dose of  GANDHAGA PARPAM 
900 mg/kg 
H,B,T,HB,NM  (Male)           
H,B,T,HB ,NM (Female) 
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Environmental conditions 
  The animals were kept in a clean environment with 12 hour light and 12 hour 
dark cycles. The air was conditioned at 22±30C and the relative humidity was 
maintained between 30-70% with 100% exhaust facility. The cages corresponding to 
each experimental group were distributed on racks in such a manner that external 
factors, such as environmental conditions, were balanced as far as possible. 
Feed & feeding schedule 
  Feed was provided adlibitum throughout the study period, except over night 
fasting (18-20 hours) prior to dose administration. After the substance has been 
administered, food was with held for a further 3-4 hours. 
Water 
  The water was offered adlibitum in bottles. There was periodically analyzed to 
detect the presence of possible contaminants 
Doses 
  The doses for the study were selected based on literature search and range 
finding study. Following the period of fasting, the animals were weighed and then 
extract was administered orally as single dose using a needle fitted on to a disposable 
syringe of approximate size at the following different doses. 
  The test item was administered as single dose. After single dose administration 
period, all animals were observed for 28 days. 
 
Dose Preparation 
  GANDHAGA PARPAM was added in distilled water and completely 
dissolved to for oral for administration. The dose was prepared of a required 
concentration before dosing by dissolving GANDHAGA PARPAM in distilled water. 
Test Group 
Dose to Animals 
(mg/kg body –weight / day Number of Animals 
Group – I CONTROL 10 ( 5 Male  and 5 Female) 
Group – II Low dose of  GP  300mg/kg 10 ( 5 Male  and 5 Female) 
Group – III Middle dose of GP 600mg/kg 10 ( 5 Male  and 5 Female) 
Group - IV High dose of  GP  900 mg/kg 10 ( 5 Male  and 5 Female) 
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It was mixed well. The preparation for different doses was vary in concentrations to 
allow a constant dosage volume. 
Administration 
  The test item was administered orally to each   rat as single dose using a 
needle fitted on to a disposable syringe of appropriate size at the following different 
doses. The concentration was adjusted according to its body weight. The volume was 
not exceeding 10 ml/kg body weight. Variability in test volume was minimized by 
adjusting the concentration to ensure a constant volume at all dose levels. 
OBSERVATIONS  
  These observations were also performed on week-ends. The observations 
included   but were not limited to changes in skin and fur, in the eyes and mucous 
membranes, in the respiratory, circulatory, central nervous and autonomous systems, 
somatomotor activity and behavior. 
Clinical signs of toxicity  
          All the rats were observed at least twice daily with the purpose of recording 
any symptoms of ill- health or behavioral changes. Clinical signs of toxicity daily for 
28 days. 
Food intake  
  Prior to the beginning of treatment, and daily, the food intake of each cage was 
recorded for period of 28 days and the mean weekly intake per rats was calculated. 
Water intake 
  Water intake was checked by visual observation during the Study. In addition, 
the water consumption in each cage was measured daily for a period of 28 days. 
Bodyweight: 
  The body weight of each rat was recorded one week before the start of 
treatment, and during the course of the treatment on the day of initial, 3rd, 7th, 10th, 
14th, 17th, 20th, 24th and 28th days (day of sacrifice). The mean weights for the 
different groups and sexes were calculated from the individual weights. 
Blood Collection  
  Blood was collected through retro-orbital sinus from all the animals of 
different groups on 28th day. The blood was collected in tubes containing 
Heparin/EDTA as an anticoagulant. Animals were fasted over night prior to the blood 
collection. 
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LABORATORY STUDIES  
    During the 4th week of treatment, samples of blood were withdrawn from the 
orbital sinus of 10 rats from each group, under light ether anesthesia after fasting for 
16 hours. The blood samples are used to evaluate Hematological   parameters like 
RBC, WBC, and PLATELETS etc….. The collected blood samples also centrifuged 
10000 rpm in 10 minutes to separate the serum. The separated serum used to evaluate 
biochemical parameters like SGOT, SGPT, ALP and BILIRUBIN ect……... 
Hematology  
The following hematological parameters were analysed using Autoanalyser  
Hb  :  Haemoglobin (g %)  
PCV   :  Packed Cell Volume 
WBC  :  White Blood Corpuscles (x103/cmm)  
RBC  :  Red Blood Corpuscles (x106/cmm)  
Blood Platelet count (x103/cmm)  
Differential WBC count:  
N  :  Neutrophils (%)  
L  :  Lymphocytes (%)  
M  :  Monocytes (%)  
E  :  Eosinophils (%)  
RDW  :  Red Cell Distribution Width. 
MPV  :  Mean Platelet Volume 
Clinical Biochemistry:  
  The following clinical Bio parameters were analysed using Auto analyser  
Total serum protein (g/dl)  
ALT/SGPT :  Alanine amino transferase (U/L)  
AST/SGOT :  Aspartate amino transferase (U/L)  
ALP   :  Alkaline serum phosphatase (U/L)  
CHL   :  Cholesterol (mg/dL)  
HDL   :  High density lipoprotein 
TG   :  Triglyceride 
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TERMINAL STUDIES  
Sacrifice and macroscopic examination 
  On completion of the 4 weeks of treatment, 18 Wister rats were sacrificed by 
ether inhalation. A full autopsy was performed on all animals which included 
examination of the external surface of the body, all orifices, cranial, thoracic and 
abdominal cavities and their contents both in situ and after evisceration. As the 
number of animals exceeded the number that could be sacrificed in one day, the 
autopsies were carried out over three consecutive days at the end of the treatment 
period.  
Organ weights: 
            After the macroscopic examination the following organs were weighed after 
separating the superficial fat: Brain, Heart, Spleen Kidneys, Testes, Liver, Lungs, 
pancreas and stomach.   
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PHARMACOLOGICAL ANALYSIS 
 
ANTI CANCEROUS ACTIVITY OF GANDHAGA PARPAM ON DALTON’S 
LYMPHOMA ASCITES IN MICE  
 
Induction of cancer using DLA cells 
  Dalton’s Lymphoma ascites (DLA) cell was supplied by Amala cancer 
research center, Trissur, Kerala, India. The cells maintained in vivo in Swiss albino 
mice by intraperitoneal transplantation. While transforming the tumor cells to the 
grouped animal the DLA cells were aspirated from peritoneal cavity of the mice using 
saline. The cell counts were done and further dilution were made so that total cell 
should be 1 x 106, this dilution was given intraperitonealy. Let the tumor grow in the 
mice for minimum seven days before starting treatments.  
Treatment Protocol    
  Swiss Albino mice were divided in to five group of six each. All the animals 
in four groups were injected with DLA cells (1 x 106 cells per mouse) 
intraperitonealy, and the remaining one group is normal control group. 
 Group 1  served as the normal control.  
 Group 2  served as the tumor control. Group 1 and 2 receives normal diet  
and Water.  
 Group 3  served as the positive control, was treated with injection  
fluorouracil at 20 mg/kg body weight, Intra peritoneally.  
Group 4  Served as a treatment control group and was  
Administered  GP at  a dose of 200mg/kg through orally.             
(LD50 OECD Guidelines) 
Group 5    Served as a treatment control group and was  
Administered  GP at a dose of 200mg/kg through orally.              
(LD50 OECD Guidelines) 
Treatment 
 In this study, drug treatment was given after the 24 hrs of inoculation, once 
daily for 14 days. On day 14, after the last dose, all mice from each group were 
sacrificed; the blood was withdrawn from each mouse by retro orbital plexus method 
and the following parameters were checked. 
1. Hematological parameters 
1) WBC count   
2) RBC count  
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3) Hb content 
4) Platelet count 
5) Packed cell volume 
2.   Serum enzyme and lipid profile 
3. Total Cholesterol                    (TC) 
4. Triglycerides                          (TG) 
5. Aspartate amino Transferase  (AST) 
6. Alanine amino Transferase    (ALT) 
7. Alkaline Phosphatase             (ALP) 
3.    Derived parameter 
1. Body weight 
2. Life span (%) 
3. Cancer Cell Count 
EVALUATION OF CLINICAL PARAMETERS  
Cancer cell count 
  The fluid (0.1ml) from the peritoneal cavity of each mouse was withdrawn by 
sterile syringe and diluted with 0.8 ml of ice cold Normal saline or sterile Phosphate 
Buffer Solution and 0.1 ml of tryphan blue (0.1 mg/ml) and total numbers of the 
living cells were counted using heamocytometer. 
                               No of cells Dilution 
   Cell count = ------------------------------------------              
                        Area × Thickness of liquid film 
6) Hematological parameters 
i) WBC count 
ii) RBC count 
iii) Platelet count 
iv) Hemoglobin 
v) Packed Cell Volume 
i) WBC count 
 The total WBC count was found to be increased in cancer control, when 
compared with normal and treated tumor-bearing mice. The total WBC count were 
found to decrease significantly in animals treated with  extract when compared with 
cancer control, indicating that the antitumor nature of the extract. 
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ii) RBC and Hb 
 RBC and Hb content decreases with tumor bearing mice when compared with 
Normal control mice. 
iii) Platelets 
 In Hodgkin lymphoma, increased in platelet count often reported in laboratory 
finding. Hence, I investigated this parameter in the study. 
iv)  Packed cell volume  
  In any case of anemia the packed cell volume is decreases.  
SERUM ENZYME AND LIPID PROFILE 
  The serum was analyzed for the following parameters 
1. Aspartate amino Transferase (AST) 
2. Alanine amino Transferase    (ALT) 
3. Alkaline Phosphatase             (ALP) 
4. Total Cholesterol                    (TC) 
5. Triglyceride                            (TG) 
1. TOTAL CHOLESTEROL AND TRIGLYCERIDE (lipid profile) 
 Abnormal blood lipid profile has been associated with cancer. In Hodgkin 
lymphoma, high cholesterol level and low triglyceride level has been reported. Hence 
I investigated this parameter in the study. 
2. LIVER ENZYMES (AST, ALT, ALP). 
  Abnormal liver function seen in patient with Hodgkin lymphoma, that these 
liver enzyme levels markedly increase in tumor bearing mice. ALP is an enzyme 
mainly derived from the liver, bones and in lesser amount from intestines, placenta, 
kidneys and leukocytes. An increase in ALP levels in the serum is frequently 
associated with the variety of disease. ALP comprises a group of enzyme that 
catalyzes the phosphate esters in an alkaline environment, generating an organic 
radical and inorganic phosphate. 
 Markedly elevated serum ALP, hyperalakline-phosphatasemia, is seen 
predominantly with more specific disorders; including malignant biliary cirrhosis, 
hepatic lymphoma and sarcoidosis. Hence, I investigated this parameter in this study. 
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DERIVED PARAMETERS 
1. Body weight: 
 All the mice were weighed, from the beginning to 15th day of the study. 
Average increase in body weight on the 15th day was determined. 
2. Percentage increase in life span (ILS)    
 All biochemical investigations were done by using COBAS MIRA PLUS-S 
Auto analyzer from Roche Switzerland. 
 Hematological test are carried out in COBAS MICROS OT 18 from Roche. 
 Newly added Hi-Tech instruments MAX MAT used for an auto analyzer for 
all biochemistry investigations in blood sample. 
Induction of Cancer Using DLA Cell 
 Dalton’s Lymphoma Ascites (DLA) cells were supplied by Amala cancer 
research center, Trissur, Kerala, India. The cells were maintained in vivo in Swiss 
albino mice by intraperitoneally transplantation. DLA cells aspirated from the 
peritoneal cavity of mice were washed with saline and given intraperitoneally to 
develop carcinoma. 
Effect of GP on Survival Time 
 Animals were divided into five groups of six animals each. Except the normal 
control group, the remaining groups were inoculated with DLA cells (1x106 
cells/mouse)intraperitoneally on day ‘0’ and treatment with GP started 24 hrs after 
inoculation, at a dose of 200mg/kg/day. p.o. The normal and tumor control group was 
treated with same volume of 0.9% sodium chloride solution. All the treatments were 
given for fourteen days. The increase in life span (ILS) of each group, consisting of 6 
mice was noted. 
   The antitumor efficacy of GP was compared with that of 5-fluorouracil (Dabur 
pharmaceutical ltd. India; 5-FU, 20 mg/kg/day, i.p, for 14 days). The ILS of the 
treated groups was compared with that of the control group using the following 
calculation: 
                   Increase in lifespan = [(T - C) / C] x 100 
Where T = number of days the treated animal survived. 
    C = number of days control animals survived. 
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EVALUATION OF ANTIOXIDANT ACTIVITY OF  GANDHAGA PARPAM 
THROUGH DPPH (2, 2-DIPHENYL 1-2 PICRYLHYDRAZYL) ASSAY 
 
  The antioxidant activity of GANDHAGA PARPAM was determined using the 
2, 2-diphenyl-1 picrylhydrazyl (DPPH) free radical scavenging assay .100µl of 
GANDHAGA PARPAM extract was mixed with 2.7ml of methanol and then 200µl of 
0.1 % methanolic DPPH was added. The suspension was incubated for 30 minutes in 
dark condition. Initially, absorption of blank sample containing the same amount of 
methanol and DPPH solution was prepared and measured as a control subsequently, at 
every 5 min interval, the absorption maximum of the solutions were measured using a 
UV double beam spectra scan (Chemito, India) at 517nm. The antioxidant activity of 
the sample was compared with known synthetic standard of 0.16% Butylated 
Hydroxy Toluene (BHT). The experiment was carried out in triplicates. 
 
  Free radical scavenging activity of GANDHAGA PARPAM calculated by the 
following formula: 
    (Abs of Control – Abs of Test) 
% Inhibition =      -------------------------------------  x 100          
   Abs of Control 
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ANTI-INFLAMMATORY ACTIVITYOF GANTHAGA PARPAM BY 
CARRAGEENAN INDUCED HIND PAW EDEMA METHOD 
  The anti-inflammatory activities of GANTHAGA PARPAM at 100 mg/kg& 
200 mg/kg doses were evaluated using carrageenan-induced paw edema method. The 
inflammation was readily produced in the form of edema with the help of irritant such 
as carrageenan. Carrageenan is a sulphated polysaccharide obtained from sea weed 
(Rhodophyceae) and when injected cause the release of prostaglandins by the way it 
produces inflammation and edema. 
 
REQUIREMENTS: 
Animal                          :  Albino rat (180-200 g) 
Drugs and chemicals    :  Carrageenan (1%w/v), Diclofenac sodium  
(standard),  Carboxy methyl cellulose (1%w/v), 
Plethysmo meter. 
Test compounds            : GANDHAGA PARPAM 
METHOD: 
  Anti-inflammatory activity was performed by the following procedure of 
Bhandri et al(1)The animals were divided into 4 groups, each groups having 6 
animals. A freshly prepared suspension of carrageenan (1% w/v , 0.1 ml) was injected 
to the planter region of left hind paw of each rat. One group was kept as control and 
the animals of the other groups were pretreated with the GANDHAGA PARPAM 
test Compounds dissolved with 2 ml sterile water given through orally 30 min before 
the carrageenan treatment. The paw volumes of the test compounds, standard and 
control groups were measured at 60,240,360 minutes of carrageenan treatment with 
the help of  plethysmometer. Mean increase in paw volume was measured and the 
percentage of inhibition was calculated. 
% Anti-inflammatory activity = (Vc-Vt / Vc) x 100 
Where, Vt-mean increase in paw volume in rats treated with test compounds, 
Vc-mean increase in paw volume in control group of rats. 
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5. MICROBIOLOGICAL ANALYSIS 
ANTI - MICROBIAL STUDIES 
Aim 
  To study the Anti-microbial action of “GANDHAGA PARPAM ” done by 
“Agar well diffusion method” – Kirby – bauyermethod. 
 
Components of Muller Hinton agar medium 
         Beef extract   -  300gms/lit 
         Agar    -  17 gms/lit 
         Starch    -  1.5 gms/lit 
         Casein Hydrolysate  -  17.5 gms/lit 
         Distilled water  -  1000 ml 
         PH   -  7.6 
 
Procedure: 
  The method of antibacterial activity study is UPS Diffusion Method. 
Antibiotic discs are prepared with known concentration of antibiotic are placed on 
agar plates that has been inoculated with the known pathogenic micro organism. The 
antibiotic diffuses through the agar producing an antibiotic concentration, gradient 
antimicrobial susceptibility is proportional to the diameter of the inhibitory zone 
around the disc. If the microorganism which grows up to the edge of the disc are 
resistant to the antimicrobial agent. The recommended medium in this method is 
Muller Hinton Agar, its PH should be between 7.2-7.6 and should be poured to 
uniform thickness of 4mm in the petri plate (25ml). 
 
Methodology: 
  Muller Hinton Agar plates are prepared and Pseudomonas, Staphylococcus 
aureus,  Escherichia coli, Candida Species is inoculated separately. 
  The prepared disc of GANDHAGA PARPAM  are placed over the incubated 
plate using sterile forceps and incubated for 24 hours at 37°C. The plates after 24 
hours incubation are observed for the zone of inhibition. 
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6. RESULTS AND DISCUSSION 
6.1. STANDARDISATION OF GANDHAGA PARPAM   
  The test drug GANDHAGA PARPAM had been subjected to various studies 
to establish the works of Siddhar`s to be true. Literary collections, physico-chemical 
and elemental analysis, pharmacological study, toxicological study and antimicrobial 
study are done to prove the activity of GANDHAGA PARPAM as an anti-diarrhoeal, 
anti-spasmodic and anti-pyretic activities. 
Table – 3 Physico Chemical Standardisation. 
SL. NO. PARA METER RESULTS 
1. Organo leptic characters  
1. Color 
2. Odour 
3. Sense of touch 
4. Taste 
5. Appearance 
 
Grey 
Pleasant odour 
Soft 
Bitter astringent 
Powder 
1. Physico chemical standard 
1. Loss on drying at 70°C 
2. Ash  
a. Total Ash 
b. Acid insoluble ash 
c. Water soluble  
3. Extractive value 
a. Ethanol soluble extractive 
b. Water soluble extractive 
4. pH value (1% solution) 
             
 
7.30 % 
 
8.25% 
0.95 % 
7.75 % 
 
8.10 % 
9.30 % 
7.540 
 
Interpretation: 
  The physical parameters like colour, odour touch, appearance revealed that 
GANDHAGA PARPAM is a Grey,  Pleasant odour,  having the  PH 7.540 slightly 
alkaline Ph. 
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Determination of loss of drying normal: 
  The loss of drying test is designed to measure the amount of volatile matters in 
a sample when the sample is dried under specified conditions moisture is one of the 
major factors.  Responsible for the deterioration of the drugs and formulations low 
moisture content is always desirable for higher  stability of days. 
  The percentage of loss on drying was within acceptable range to thus implying 
that the formulation can be stored for a long period and would not easily be attacked 
by microbes. 
 
Total Ash: 
  Ash values are helpful in determining the quality and purity of crude drugs.  in 
this trial drug GANDHAGA PARPAM (The minerals that present in the trial drug are 
calcium, chloride, sulphate). The salts, Ca+, Cl-, Sulphate are not harmful one. In this 
trial drug GANDHAGA PARPAMis used as a condensation  from water extraction .    
So only water soluble trace elements present here in a very few trace levels. The total 
ash was 8.25%. 
 
Acid insoluble Ash: 
  Acid insoluble ash values represents detecting the presence of silica and 
oxalate in a drugs. In my drug the silica and oxalate that is the acid insoluble ash is 
very low on 0.95 ± 0.011. So the drug has high quality. 
 
Water soluble ash: 
  Water soluble ash also indicate the purity of the drug water soluble ash higher 
than acid insoluble ash represents good quality of the drug which is GANDHAGA 
PARPAM is 7.75 %. So water soluble ash is higher than acid insoluble ash. 
 
b)Water soluble extractive 
               Proceed as directed for the determination of Alcohol-soluble extractive , 
using chloroform water instead of ethanol water soluble extractive GANDHAGA 
PARPAM is 9.30 %. 
 
 
  
   95 PRE CLINICAL  STUDY OF  GANDHAGA PARPAM 
 
c)Alcohol soluble extractive 
                Macerate 5g of the air dried drug, coarsely powdered, with 100ml of alcohol 
of the specified strength in a closed flask for 24 hrs, shaking frequently during six 
hours and allowing to stand for eighteen hours. Filter rapidly, taking precautions 
against loss of solvent, evaporate 25 ml of the filtrate to dryness in a tared flat 
bottomed shallow dish, and dry at 105o,to constant weight and weigh. Calculate the 
percentage of alcohol-soluble extractive with reference to the air-dried drug. Alcohol 
soluble extractive GANDHAGA PARPAM is 8.10 %. 
 
d)Determination of pH  
  5 gms of Ganthaga Parpam was weighted accurately and placed in clear 
100ml beaker. Then 50ml of distilled water was added to it and dissolved well. after 
30 minutes it was then applied into pH meter at standard buffer solution of  4.0,  7.0 
and  9.0. Repeat the test 4 times and average was recorded. The pH of GANDHAGA 
PARPAM is 7.540. 
Microbial Limit Tests 
 Results of Microbial Contamination Test 
S.No. Test Particulars 
Colony Counts 
(CFU/ g) 
Limits Value 
(CFU/g) 
1. Total  Viable Aerobic Bacterial Count 4 x 102 1 x 105 
2. Total  Viable Fungal Count 3.5 x 102 1 x 103 
 
Results of Specific Pathogens Test 
S.No. Test for Specified Pathogens 
Colony Counts 
(CFU/ g) 
Limits Value 
(CFU/g) 
1. Salmonella sp.  No growth - 
2. Staphylococcus aureus No growth - 
3. Escherichia coli 
No growth 
 
- 
4. 
 
Pseudomonas aeruginosa No growth - 
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Interpretation: 
  The total bacterial count and the total fungal count of the drug were found to 
be within the WHO prescribed limits which indicate that the drug is free from 
microbial contamination. The other pathogens like Escherichia coli, Salmonella sps, 
Pseudomonas aeruginosa and Staphylococcus aureus were found to be completely 
absent in the drugs.   
 
Disintegration: 
  The disintegration of test sample under the  specifications not more than 15 
minutes. In the present analysis the GANDHAGA PARPAM disintegration on only 
10m 50 sec. 
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BIO-CHEMICAL ANALYSIS 
Table – 4  Results of Preliminary test for basic and acidic radicals 
S.NO EXPERIMENT INFERENCE 
1. Test for Calcium  Absent 
2. Test for Sulphate Present 
3. Test for Chloride Present 
4. Test for Carbonate Absent 
5. Test for Starch Absent 
6. Test for Ferric Iron Absent 
7. Test for Ferrous Iron Absent 
8. Test for Phosphate Absent 
9. Test for Albumin Absent 
10. Test for Tannic Acid Absent 
11. Test for Unsaturated Compounds Absent 
12. Test for Reducing Sugar Absent 
13. Test for Amino Acid Absent 
14. Test for Zinc Absent 
 
INTERPRETATION: 
   The biochemical analysis  of GANDHAGA PARPAM contains the following 
chemical constituents, Sulphate, Chloride. 
 
SULPHATE: 
 It significantly improves the joint function. It helps in reduce the pain and 
inflammation. 
 Sulphate’s primary biological role in halting or reversing joint degeneration. 
 Nutritionally essential element 
 Functional in the form of sulphur containing amino acids.  
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CHLORIDE: 
 Calcium- activated chloride channels (Ca-Cl) are thought to regulate neuronal 
excitability and recently chloride regulation in DRG (Dorsal root ganglion) 
neurons has attracted much attention in pain research. 
 Chloride forms the chief anion of the extracellular fluid and exists along with 
sodium mostly. 
 Regulates acid base balance. 
 Formation of HCl in gastric juice 
 Help to preserve normal neuromuscular irritability by maintaining a state of 
equilibrium, on account of their relative proportion in ECF and ICF.  
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PHYTOCHEMICAL STUDY OF GANDHAGA PARPAM 
  The GANDHAGA PARPAM was subjected to qualitative chemical 
investigation Details of the various tests performed for the presence of phyto 
constituents is shown in Table 5.  
Table – 5  Phytochemical tests for GANDHAGA PARPAM 
 
Tests 
 
GANDHAGA 
PARPAM 
Alkaloids  
Mayer’s test  -ve  
Dragendroff’s test  -ve 
Hager’s test  +ve  
Carbohydrates and glycosides  
Molisch test  +ve  
Legal’s test  -ve  
Borntrager’s test for anthraquinones  -ve  
Phytosterols  
Liebermann-Burchard test  -ve  
Salkowski test  -ve  
Flavanoids  
Shinoda test  
Magnesium turnings and hydrochloric acid  
(Presence of red color)  
-ve  
Fluorescence test  -ve  
Tannins  
Ferric chloride test  -ve  
Potassium dichromate test  -ve  
Lead acetate test  +ve  
Proteins  
Millon’s test  -ve  
Biuret test  -ve  
Ninhydrin test  -ve  
Fixed oils and fats  
Spot test  -ve  
Saponification test  -ve  
Lignin  
Phloroglucinol test  -ve  
Saponins  
Frothing test  -ve  
 
(+ve) indicates the presence of phytochemical, (-ve) indicates the absence of 
phytochemical. 
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INTERPRETATION: 
Alkaloids-decreased gastric acid secretion and inhibit the gastric motility 
Tannins-Tannins react with tissue promote tissue proteins. 
This study revealed the presence of active phytochemicals in GANDHAGA PARPAM 
such as alkaloids, carbohydrates, glycosides, tannins. 
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INSTRUMENTAL ANALYSIS 
SCANNING ELECTRON MICROSCOPE (SEM) 
 
SEM -1600 Magnification 
 
SEM -3000 Magnification 
Figure - 6 Showing SEM Results of Trial Drug                                                              
(GANDHAGA PARPAM) 
  
  
   102 PRE CLINICAL  STUDY OF  GANDHAGA PARPAM 
 
INTERPRETATION : 
  The morphology of the GANDHAGA PARPAMsamples can be determined by 
Environmental SEM (FEI Quanta). A representative portion of each sample must be  
sprinkled onto a double side carbon tape and mounted on aluminium stubs, in order to 
get a higher quality secondary electron image for SEM examination. The SEM 
photographs revealed that particles were spherical in shapes and sizes were in the 
range from 1µm to 5µm.Although the particle sizes of different batches showed 
similarity, it seems that these particles were aggregates of much smaller particles.  
  When dispersed in an aqueous medium, these preparations form a negatively 
charged hydrophobic particle suspension. This hydrophobicity gave these particles a 
tendency to aggregate together to form larger particles. GANDHAGA PARPAM 
exhibited larger sizes and agglomeration of the particles. Therefore, the comparatively 
larger size may be due to the agglomeration of the particles by repeated cycles of 
calcinations involved in preparation. SEM analysis of the GANDHAGA PARPAM 
shows most of the particles present in the sample are nano size, average particle size 
is 40-20µm. 
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FOURIER TRANSFORM-INFRARED SPECTROSCOPY( FTIR) 
 
  Fourier Transform Infra-Red Spectroscopy (FTIR) analysis results in 
absorption spectra that provide information about the functional group and molecular 
structure of a material IR relates with the sample and the bonds among atoms in the 
molecule stretch and bend, absorbing infrared energy and creating the infrared 
spectrum. It is of two kinds of bending and stretching. 
  FT-IR is a very useful tool in the recognition of the functional groups of bio 
molecules, thus aiding in their structural elucidation, so confirming the presence of 
active molecules responsible for the therapeutic activity of Siddha drugs. The results 
of Table no: 6 and Fig no: 7 shows the presence of functional group and inorganic 
compounds of GANDHAGA PARPAM 
 
 
Figure -7  Showing FTIR Image of GANDHAGA PARPAM 
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Table – 6  Interpretation of FTIR Spectrum 
 
S.No Frequency Bond Functional Group 
1. 2881.65 C-H Stretching Alkane 
2. 2358.94 O=C=O Stretching Carbon-di-oxide 
3. 464.84 C-X Stretching Bromide, Iodide 
 
INTERPRETATION: 
1. FTIR instrumental analysis was done. The test drug was identified to have 3 
peaks. They are the functional groups present in the trial drug GANDHAGA 
PARPAM 
2. It confirms that GANDHAGA PARPAM constitutes Alkanes, Carbon-di-oxide, 
bromide, Iodide as functional  groups.  
 
ALKANES:  
  They protect against bacteria and fungal infections. 
 
BROMIDE: 
  Bromides were widely used as sedative and antiepileptic. Bromide ion causes 
secondary anion potentiation of gamma – aminobutyric acid (GABA) channels in the 
CNS.  
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ICP-OES of GANDHAGA PARPAM 
GANDHAGA PARPAM (wt:0.41210g) 
 
Elements Wavelength 
(nm) 
Concentration 
Al 396.152 BDL 
As 188.979 BDL 
Ca 315.807 10.180 mg/l 
Cd 228.802 BDL 
Cu 327.393 BDL 
Fe 238.204 11.376 mg/l 
Hg 253.652 BDL 
K 766.491 03.821 mg/l 
Mg 285.213 01.104 mg/l 
Na 589.592 14.320 mg/l 
Ni 231.604 BDL 
Pb 220.353 BDL 
P 213.617 186.34 mg/l 
S 180.731 41.204 mg/l 
Zn 206.200 3.210 mg/l 
 
BDL: Below Detectable Limit (Normal-1ppm) 
     1%  = 10000ppm, 
     1ppm = 1/1000000 or 0.0001% 
Toxic metals and the permissible limits 
Heavy metals WHO & FDA limits 
Arsenic(As) 10ppm 
Mercury(Hg) 1ppm 
Lead (pb) 10ppm 
Cadmium (Cd) 0.3ppm 
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INTERPRETATION 
 This result indicates the presence of Calcium, Iron, Potassium, Sodium, 
Magnesium, Phosporus, Sulphur, Zinc 
 Calcium is essential for maintaining the necessary level of bone mass. The 
body is constantly using calcium for the muscles and nerves. Maintenance of 
plasma calcium level within normal range is of vital importance because 
neuro-muscular excitability is dependent on plasma calcium level.  
 Phosphorous, it decreases urine calcium, reduces demineralization of bone 
and increases calcium balance. It is an important constituent of phosphate 
buffers in the blood and urine. It is required for the formation of certain 
physiologically important phosphorus containing compounds like 
phospholipids, coenzymes and enzymes of intermediary metabolism. 
Contributes formation of ATP, ADP and creatine phosphate.
 [24] 
 Sodium and Potassium: In the presence of Sodium and Potassium regulate 
the acid-base balance of the body fluids . They help to preserve the 
neuromuscular irritability by maintaining a state of equilibrium on account of 
their relative proportion in the ECF and ICF.  
 Magnesium is a cofactor that regulates diverse biochemical reactions in the 
body, including protein synthesis, muscle, nerve function, blood glucose 
control and blood pressure regulation  
 Zinc may be regarded as an antioxidant, protects the body against free radical 
damage and cell damage. Zinc is important for a healthy immune system. It 
enhances absorbtion of iron.It can produce healthy veins and arteries that 
enhance the blood circulation. 
 Sulphate may prevent the occurrence of any  infection, sulphate is potent anti 
oxidant activity in human body. 
 Ferrous Iron Iron help to preserve many vital functions in the body, including 
general energy and focus, gastrointestinal processes, the immune system and 
regulation of body temperature. 
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XRD (X-Ray Diffraction): 
   X-Ray powder diffraction is a rapid analytical technique primarily 
used for phase identification of a crystalline material and can provide information on 
unit cell dimensions.  
 
Fig. No. 8 XRD –Results of  GANDHAGA PARPAM 
 
  This XRD finger print shows both the similarities and differences of the 
sample successfully and is a valuable primary tool for checking the quality control of 
Herbo-mineral formulations. The different peaks show the presence of minerals in the 
samples. 
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TOXICITY STUDIES 
EVALUATION OF ACUTE TOXICITY STUDY OF  
Effect of Acute Toxicity Study (14 Days) of GANDHAGA PARPAM 
Table no –7   Physical and behavioral examinations. 
Group 
no. 
Dose(mg/kg) Observation 
sign 
No. of animal affected. 
Group-I 5mg/kg Normal 0 of 3 
Group- II 50mg/kg Normal 0 of 3 
Group-III 300mg/kg Normal 0 of 3 
Group-IV 1000mg/kg Normal 0 of 3 
Group-V 2000mg/kg Normal 0 of 3 
Table no- 8    Home cage activity 
Functional 
and 
Behavioural 
observation 
Observation 
5mg/kg 
Group 
(G-I) 
50mg/kg 
(G-II) 
300mg/kg 
(G-III) 
 
1000mg/kg 
(G-IV) 
2000mg/kg 
(G-V) 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Body 
position Normal 3 3 3 3 3 
Respiration Normal 3 3 3 3 3 
Clonic 
involuntary 
Movement 
Normal 3 3 3 3 3 
Tonic 
involuntary 
Movement 
Normal 3 3 3 3 3 
Palpebral 
closure Normal 3 3 3 3 3 
Approach 
response Normal 3 3 3 3 3 
Touch 
response Normal 3 3 3 3 3 
Pinna reflex Normal 3 3 3 3 3 
Tail pinch 
response Normal 3 3 3 3 3 
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Table no- 9 Hand  held  observation 
Functional and 
Behavioral 
observation 
Observation Control 5  
mg/ kg 
(G-I) 
50 
mg/kg 
(G-II) 
300 
mg/kg 
(G-III) 
1000 
mg/kg 
(G-IV) 
2000 
mg/kg 
(G-V) 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Reactivity Normal 3 3 3 3 3 3 
Handling Normal 3 3 3 3 3 3 
Palpebral 
closure 
Normal 3 3 3 3 3 3 
Lacrimation Normal 3 3 3 3 3 3 
Salivation Normal 3 3 3 3 3 3 
Piloerection Normal 3 3 3 3 3 3 
Pupillary 
reflex 
Normal 3 3 3 3 3 3 
Abdominal 
tone 
Normal 3 3 3 3 3 3 
Limb tone Normal 3 3 3 3 3 3 
 
Table no-10   Mortality 
Group no Dose no(mg/kg) Mortality 
Group-I 5(mg/kg) 0 of 3 
Group-II 50(mg/kg) 0 of 3 
Group-III 300(mg/kg) 0 of 3 
Group-IV 1000(mg/kg) 0 of 3 
Group-V 2000(mg/kg) 0 of 3 
 
RESULT: 
 From acute toxicity study it was observed that the administration of 
GANDHAGA PARPAM at a dose of 2000 mg/kg to the rats do not produce drug-
related toxicity and mortality. So No-Observed-Adverse-Effect- Level (NOAEL) of 
GANDHAGA PARPAM is 2000 mg/kg. 
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DISCUSSION 
 GANDHAGA PARPAM was administered single time at the dose of 
5mg/kg, 50mg/kg , 300mg/kg, 1000mg/kg and 2000mg/kg to rats and observed for 
consecutive 14 days after administration. Doses were selected based on the pilot 
study and literature review. All animals were observed daily once for any abnormal 
clinical signs. Weekly body weight and food consumption were recorded. No 
mortality was observed during the entire period of the study. Data obtained in this 
study indicated no significance physical and behavioural signs of any toxicity due 
to administration of GANDHAGA PARPAM at the doses of 5mg/kg, 50mg/kg , 
300mg/kg, 1000mg/kg and 2000mg/kg to rats.  
 At the 14th day, all animals were observed for functional and behavioral 
examination. In functional and behavioral examination, home cage activity, hand 
held activity were observed. Home cage activities like Body position, Respiration, 
Clonic involuntary movement, Tonic involuntary movement, Palpebral closure, 
Approach response, Touch response, Pinna reflex, Sound responses, Tail pinch 
response were observed. Handheld activities like Reactivity, Handling, Palpebral 
closure, Lacrimation, Salivation, Piloercetion, Papillary reflex, abdominaltone, 
Limb tone were observed. Functional and behavioral examination was normal in all 
treated groups.Food consumption of all treated animals was found normal as 
compared to normalgroup. 
 Body weight at weekly interval was measured to find out the effect of 
GANDHAGA PARPAM on the growth rate. Body weight change in drug treated 
animals was found normal. 
 
INTERPRETATION: 
 
 GANDHAGA PARPAM was administered single time at the dose of 
5mg/kg, 50mg/kg , 300mg/kg, 1000mg/kg and 2000mg/kg to rats and observed for 
consecutive 14 days after administration. Doses were selected based on the pilot 
study and literature review. All animals were observed daily once for any abnormal 
clinical signs. Weekly body weight and food consumption were recorded. No 
mortality was observed during the entire period of the study. Data obtained in this 
study indicated no significance physical and behavioural signs of any toxicity due 
to administration of GANDHAGA PARPAM at the doses of 5mg/kg, 50mg/kg , 
300mg/kg, 1000mg/kg and 2000mg/kg to rats.  
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  At the 14th day, all animals were observed for functional and behavioral 
examination. In functional and behavioral examination, home cage activity, hand 
held activity were observed. Home cage activities like Body position, Respiration, 
Clonic involuntary movement, Tonic involuntary movement, Palpebral closure, 
Approach response, Touch response, Pinna reflex, Sound responses, Tail pinch 
response were observed. Handheld activities like Reactivity, Handling, Palpebral 
closure, Lacrimation, Salivation, Piloercetion, Papillary reflex, abdominaltone, 
Limb tone were observed. Functional and behavioral examination was normal in all 
treated groups.Food consumption of all treated animals was found normal as 
compared to normalgroup. 
  Body weight at weekly interval was measured to find out the effect of 
GANDHAGA PARPAM on the growth rate. Body weight change in drug treated 
animals was found normal. 
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SUB-ACUTE TOXICITY STUDY IN WISTAR RATS TO EVALUATE 
TOXICITY PROFILE OF GANDHAGA PARPAM 
Table :11 EFFECT OF SUB- ACUTE DOSE (28 DAYS)OF GANDHAGA 
PARPAM ON BODY WEIGHT IN GRAM 
 
GROUP CONTROL LOW MID HIGH 
1st day 124.3±1.03 127±1.543 126.3±2.231 128.3±2.23 
7th day 134.3±1.03 133.3±1.343 133±2.113 139±2.11 
14th day 136.1±1.004 104.3±1.12 104.4±2.012 105.4±2.012 
21st day 105.3±2.120 112.2±1.501 106±1.131 107±1.13 
28th day 115.3±1.041 114.3±1.202 145±2.0405 148±2.040 
 
 
Values are expressed as mean ± SEM Statistical significance (p) calculated by one 
way ANOVA followed by Dunnett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group. 
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EFFECT OF SUBACUTE DOSE (28 DAYS) OF GANDHAGA PARPAM 
Table : 12 GANDHAGA PARPAM ON ORGAN WEIGHT (PHYSICAL 
PARAMETER) IN GRAM 
GROUP CONTROL LOW  MID HIGH 
HEART 0.63±0.02 0.44±0.04 .51±0.11 0.61±0.02 
LIVER 2.51± 0.23 2.53±0.23 2.40±0.01 2.43± 0.23 
LUNGS .51±0.10 0.51±0.14 0.70±0.24 .63±0.10 
KIDNEY L 0.63±0.02 0.72±0.03 0.63±0.02 0.61±0.02 
 R 0.61±0.024 0.44±0.02 0.61±0.24 0.62±0.24 
 
Values are expressed as mean ± SEM Statistical significance (p) calculated by one 
way ANOVA followed by Dunnett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group.  
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EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF GANDHAGA PARPAM ON 
HAEMATOLOGICAL PARAMETERS 
Table no 13 
 
Drug 
treatm
ent 
RBC 
millio
n 
cells/c
mm 
WBC  
cells/cm
m 
Haemogl
obin 
gm % 
Differential count % 
Neutro
phils 
Eosinop
hils 
Monocy
te 
Lympho
cyte 
Contr
ol 
4.41±0
.40 
5272.41±
23.32 
14.60±0.
45 
33.27±1
.20 
4.73±0.
11 
0.65±0.
15 
25.13±3.
32 
LOW 4.67±0
.20 
5354.04±
23.22 
16.20±0.
43 
27.54±1
.41 
2.30±0.
14 
0.42±0.
30 
25.22±3.
51 
MID 4.53±0
.21 
5324.25±
32.35 
16.11±1.
03 
32.32±2
.22 
3.64±0.
12 
0.4052±
0.40 
25.13±3.
32 
HIGH 4.36±0
.21 
5198.25±
32.35 
18.11±1.
03 
30.32±2
.22 
3.70±0.
12 
0.54±0.
40 
26.13±3.
32 
 
Values are expressed as mean ± SEM Statistical significance (p) calculated by one 
way ANOVA followed by Dunnett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group.  
 
1
2
3
4
5
6
Control GP   200mg GP   400mg GP   600mg 
RBC
  
   115 PRE CLINICAL  STUDY OF  GANDHAGA PARPAM 
 
 
 
 
 
 
5100
5150
5200
5250
5300
5350
5400
Control GP   200mg GP   400mg GP   600mg 
WBC
10
11
12
13
14
15
16
17
18
19
20
Control GP   200mg GP   400mg GP   600mg 
HAEMOGLOBIN
22
24
26
28
30
32
34
Control GP   200mg GP   400mg GP   600mg 
NEUTROPHILS
  
   116 PRE CLINICAL  STUDY OF  GANDHAGA PARPAM 
 
 
 
 
 
 
 
 
1
2
3
Control GP   200mg GP   400mg GP   600mg 
EOSINOPHILS
0
1
2
3
4
5
Control GP   200mg GP   400mg GP   600mg 
MONOCYTE
50
52
54
56
58
60
62
64
66
68
Control GP   200mg GP   400mg GP   600mg 
LYMPOCYTE
  
   117 PRE CLINICAL  STUDY OF  GANDHAGA PARPAM 
 
Table : 14 EFFECT OF SUB- ACUTE DOSE(28 DAYS)OF GANDHAGA 
PARPAM ON BIOCHEMICAL PARAMETERS 
 
 
Drug 
Treatment 
SGPT 
(IU/L) 
SGOT 
(IU/L) 
ALP 
(IU/L) 
Urea 
(mg/dl) 
Creatinine 
(mg/dl) 
Control 44.14±3.0 44.24±4.31 245.12±11.32 57.35±3.00 0.74±0.03 
LOW 44.13±3.22 43.23±4.01 253.11±12.42 42.53±2.42 0.70±0.04 
MID 42.21±4.44 46.31±2.21 247.45±4.14 41.12±2.22 0.65±0.04 
HIGH 44.21±4.44 42.31±2.21 236.45±4.14 42.12±2.22 0.66±0.04 
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EFFECT OF SUB- ACUTE DOSE (28 DAYS) OFG PBIOCHEMICAL 
PARAMETERS 
 
GROUP CONTROL G P 
(200mg/kg) 
G P 
(400mg/kg) 
G P 
(600mg/kg) 
TOTAL 
BILIRUBIN 
(mg/dl) 
0.508±0.2457 0.658±0.27 0.8198±0.76 0.64±0.9 
  
Values are expressed as mean ± SEM Statistical significance (p) calculated by one-
way ANOVA followed by Dunnett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group.  
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Table: 15  EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF GANDHAGA 
PARPAM  ON FOOD INTAKE IN GRAM 
 
 
GROUP CONTROL L M H 
1st DAY 21.33±13.6110 22.1672±15.3 15.10±22.71 20.5±8.62 
7th DAY 18.5±12. 13.863±13.67 19.73±10.853 14.17±15.41 
14th DAY 21.83±8.72 13.83±15.28 13±14.96 22.72±9.981 
21st DAY 14.87±13.4 18±8.466 18.88±10.43 22.17±9.02 
28th DAY 15.10±11.38 21.38±11.50 13±8.90 13±7.57 
 
Values are expressed as mean ± SEM Statistical significance (p) calculated by one-
way ANOVA followed by Dunnett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group 
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Table: 16  Effect of Sub- Acute Dose (28 Days) Of GANDHAGA PARPAM On 
Water Intake in ml 
GROUP CONTROL GP 
(200mg/kg) 
GP 
(400mg/kg) 
GP 
(600mg/kg) 
1st DAY 98.38±13.5110 89.1672±14.26 102.10±21.99 67.5±7.03 
7th DAY 85.5±11.7938 100.63±12.60 76.6673±9.63 81.6717±14.40 
14th DAY 58.3383±8.72817 90.83±14.22 80±13.92 89.1672±8.81 
21st DAY 91.6687±12.4949 85±8.62 65.88±9.430 89.1717±8.02 
28th DAY 82.10±11.3840 88.3348±11.5004 80±8.90061 70±7.57773 
 
Values are expressed as mean ± SEM Statistical significance (p) calculated by one-
way ANOVA followed by Dunnett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group 
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Table: 17  EFFECT OF SUB ACUTE DOSES (28 DAY) OF GANDHAGA 
PARPAM ON ELECTROLYTES: - 
 
Values are expressed as mean ± SEM Statistical significance (p) calculated by one-
way ANOVA followed by Dunnett’s(n=6); NS- non-significant, *p<0.05, 
**p<0.01, ***p<0.001, calculated by comparing treated groups with control group. 
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CONTROL GP  (200mg/kg) GP   (400mg/kg) GP   (600mg/kg)
SODIUM
GROUP CONTROL GP (200mg/kg) 
GP 
(400mg/kg) 
GP 
(600mg/kg) 
Sodium (mg/dl) 145.10±0.55 146.30±0.62 141±0.1 151.80±0.70 
Calcium(mg/dl) 12.50±0.189 13.20±0.83*** 12.7±0.1*** 16.10±0.11*** 
Phosphorus 
(U/L) 8.8±0.017 6.0±0.019915ns 7.30±0.01ns 8.7±0.32* 
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RESULTS: 
CLINICAL SIGNS: 
All animals in this study were free of toxic clinical signs throughout the dosing   
period of 28 days. 
Mortality: 
All animals in control and in all the treated dose groups survived throughout the 
dosing period of 28 days. 
 Body weight: 
Results of body weight determination of animals from control and different dose 
groups exhibited comparable body weight gain throughout the dosing period of 28 
days. 
Food consumption: 
During dosing and the post-dosing recovery period, the quantity of food consumed 
by animals from different dose groups was found to be comparable with that by 
control animals. 
Organ Weight: 
Group Mean Relative Organ Weights (% of body weight) are recorded in Table 
No.12 Comparison of organ weights of treated animals with respective control 
animals on day 29 was found to be comparable similarly. 
Hematological investigations: 
The results of hematological investigations conducted on day 29 revealed 
following significant changes in the values of different parameters investigated 
when compared with those of respective controls; however, the increase or 
decrease in the values obtained was within normal biological and laboratory limits 
or the effect was not dose dependent. 
Biochemical Investigations: 
Results of Biochemical investigations conducted on the day 29th and recorded in 
Table no 14 revealed the following significant changes in the values of hepatic 
serum enzymes studied. When compared with those of respective control. 
However, the increase or decrease in the values obtained was within normal 
biological and laboratory limits. 
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INTERPRETATION: 
1)  All the animals from control and all the treated dose groups up to 15ml/kg 
survived throughout the dosing period of 28 days. 
2)  No signs of toxicity were observed in animals from different dose groups during 
the dosing period of 28 days. 
3)  Animals from all the treated dose groups exhibited comparable body weight 
gain with that of controls throughout the dosing period of 28 days. 
4) Food consumption of control and treated animals was found to be comparable 
throughout the dosing period of 28 days 
5)   Haematological analysis conducted at the end of the dosing period on day 29th, 
revealed no abnormalities attributable to the treatment. 
6) Biochemical analysis conducted at the end of the dosing period on day 29th, no 
abnormalities attributable to the treatment. 
7) Organ weight data of animals sacrificed at the end of the dosing period was 
found to be comparable with that of respective controls. 
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PHARMACOLOGICAL RESULTS 
ANTI CANCEROUS ACTIVITY OF  SIDDHA PREPARATION GANDHAGA 
PARPAM ON  DALTON’S LYMPHOMA ASCITES IN MICE 
 
Table No.18 -Effect of GANDHAGA PARPAM on Hematological parameters 
G1 – Normal Control, G2 – Cancer Control, G3 – Positive control, G4 – Treatment 
control (MEA), G5 – Treatment control (MEC) 
All values are expressed as mean ± SEM for 6 animals in each group. 
**a – Values are significantly different from Normal control (G1) at P < 0.001 
*b – Values are significantly different from cancer control (G2) at P < 0.01 
**b – Values are significantly different from cancer control (G2) at P < 0.001 
  
TREATMENT 
Total WBC 
Cells 
/mlx103 
Rbc Count 
Mill/cumm 
Hb 
Gm/dl 
PCV % 
Platelets 
Lakhs/cumm 
G1 9.97 ±3.30 5.49±2.99 14.44 ±4.44 36.67±4.86 5.22±2.81 
G2 
15.17 
±4.67a** 
4.54±2.50a** 
6.34  
±2.82a** 
38.47±5.57a** 3.62±2.64a** 
G3 
9.57 
±3.94b** 
5.97±2.87b** 12.6±3.82b** 21.23±4.62b** 4.69±2.56b** 
G4 12.57±4.97b* 4.46±2.66b* 12.92±3.26b* 20.47±4.97b* 5.12±2.53b* 
G5 
10.62 
±4.54b* 
4.50±2.84b* 12.82±3.80b* 26.26±3.62b* 5.34 ±2.76b* 
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Fig. No.9 -Effect of Effect of GANDHAGA PARPAM on Hematological 
parameters 
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Table No.19 
Effect of GANDHAGA PARPAM on serum Enzymes and lipid proteins 
Treatment Cholesterol (mg/dl) 
TGL 
(mg /dl) 
AST 
(U/L) 
ALT 
(U/L) 
ALP 
(U/L) 
G1 98.32±5.67 127.6±6.52 36.46 ±3.32 34.42 ±3.34 130.37 ±4.32 
G2 144.97±6.62a** 206.47±8.42a** 88.47±4.82a** 58.22±4.27a** 242.52±6.30a** 
G3 112.52±5.94b** 152.57±5.82b** 
56.27 
±3.82b** 
44.42±3.72b** 167.32±4.42b** 
G4 127.27±5.42b* 167.52±4.24b* 75.24 ±4.34b* 48.56±3.80b* 196.37±5.42b* 
G5 124.32±4.57b* 165.24±4.42b* 74.42±3.94b* 47.52 ±3.27b* 190.67±4.67b* 
 
All values are expressed as mean ± SEM for 6 animals in each group. 
G1 – Normal Control, G2 –Cancer Control, G3 –Positive control, G4 –Treatment 
control (MEA), G5– Treatment control (MEC). 
All values are expressed as mean ± SEM for 6 animals in each group. 
**a – Values are significantly different from control (G1) at P < 0.001 
*b – Values are significantly different from cancer control (G2) at P < 0.01 
**b – Values are significantly different from cancer control (G2) at P < 0.001 
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Fig. No. 10 
 Effect of GANDHAGA PARPAM on serum Enzymes and lipid proteins 
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Table No.20 
Effect of GANDHAGA PARPAM on the life span, body weight and cancer cell 
count of tumor induced mice. 
Treatment 
Number of 
animals 
% ILS Life span 
Increase in 
Body weight 
grams 
Cancer cell 
count 
ml X 106 
G1 6 >30 days 5.22±2.52 - 
G2 6 48% 10.86±3.12a** 5.62±2.34a** 
G3 6 88% 6.74±2.57b** 4.41±2.33b** 
G4 6 68% 7.58±2.82b* 5.17±2.49b* 
G5 6 66% 7.15±2.92b* 4.10±2.42b* 
All values are expressed as mean ± SEM for 6 animals in each group. 
G1 – Normal Control, G2 –Cancer Control, G3 –Positive control, G4 –Treatment 
control (MEA), G5– Treatment control (MEC). 
**a – Values are significantly different from normal control (G1) at P < 0.001 
*b – Values are significantly different from cancer control (G2) at P < 0.01 
**b – Values are significantly different from cancer control (G2) at P < 0.001 
Fig . No. 11 
Effect of GANDHAGA PARPAM on the life span, body weight and cancer cell 
count of tumor induced mice. 
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INTERPRETATION : 
                In DLA tumor bearing, a regular rapid increase in ascitic tumor volume was 
observed. Ascitic fluid is the direct nutritional source for tumor cells and a rapid 
increase in ascitic fluid with tumor growth would be a means to meet the nutritional 
requirement of tumor cells. Treatment with GANDHAGA PARPAM inhibited the 
tumor volume, viable tumor cell count and increased the life span of the tumor 
bearing mice. The reliable criteria for judging the value of any anticancer drug are the 
prolongation of the lifespan of animals. It may be concluded that  GANDHAGA 
PARPAM  by decreasing the nutritional fluid volume and arresting the tumor growth 
increases the life span of DLA bearing mice. Thus GANDHAGA PARPAM have 
anticancer activity against DLA bearing mice. 
             Usually, in cancer chemotherapy the major problems that are being 
encountered are of myelo suppression and anemia. The anemia encountered in tumor 
bearing mice is mainly due to reduction in RBC or hemoglobin percentage and this 
may occur either due to iron deficiency or due to hemolytic or myelopathic 
conditions. Treatment with GANDHAGA PARPAM brought back the hemoglobin 
(Hb) content, RBC and WBC count more or less to normal levels significantly. This 
clearly indicates that GANDHAGA PARPAM possess protective action on the 
haemopoietic system. 
           It was reported that the presence of tumor in the human body or in the 
experimental animals is known to affect may function of the liver. The significantly 
elevated level of total cholesterol, TG, AST, ALT, ALP in serum of tumor inoculated 
animal indicated liver damage and loss of functional integrity of cell membrane. The 
significant reversal of these changes towards the normal by GANDHAGA PARPAM 
treatments. 
            In the present study, the biochemical examination of DLA inoculated animals 
showed marked changes indicating the toxic effect of the tumor. The normalization of 
these effects observed in the serum treated with GANDHAGA PARPAM supported the 
potent antitumor and hepatoprotective   effect of the GANDHAGA PARPAM 
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Figure No. 1 – NORMAL CONTROL (UTERUS.) 
 
 
                                  
 
SECTION SHOW STRUCTURE OF UTERUS  WITH CERVIX APPEAR NORMAL 
 
Figure No.2 – TUMOR CONTROL (UTERUS.) 
 
 
 
 
 
SECTION SHOW STRUCTURE OF UTERUS  WITH CERVIX CANCER 
  
Fig. No. 12   HISTOPATHOLOGY 
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Figure No. 3 – STANDARD CONTROL (UTERUS.) 
 
 
 
SECTION SHOW STRUCTURE OF UTERUS  WITH NO CERVIX CANCER 
  
Figure No.4 – TREATED WITH ld (UTERUS) 
 
 
 
 
SECTION SHOW STRUCTURE OF UTERUS  WITH NO CERVIX CANCER 
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Figure No.5 – TREATED WITH  hd (LIVER)  
 
 
SECTION SHOW STRUCTURE OF UTERUS  WITH NO CERVIX CANCER 
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ANTI-OXIDANT ACTIVITY OF SIDDHA PREPARATION GANDHAGA 
PARPAM BY DPPH RADICAL SCAVENGING ASSAY 
Table No.21. Anti-oxidant activity of GANDHAGA PARPAM 
 
Sample 
concentration 
(µg/ml) 
Absorbance Percentage of Inhibition 
GP Standard GP Standard 
Control 0.5461 0.354 - - 
1.25 0.4921 0.262 9.8 27 
2.50 0.3825 0.182 30 48 
5 0.2782 0.104 49 62 
10 0.1820 0.082 66 76 
20 0.1025 0.076 70 78 
 
µg/ml: microgram per millilitre.  
Drug:  GANDHAGA PARPAM (1.25-20µg/ml). Standard: BHT  (10mg/ml )  
IC 50 value of GP   = 10 µg/ml IC 50 value of STD   = 5 µg/ml 
Fig. No. 13. Anti-oxidant activity of GANDHAGA PARPAM 
 
 
INTERPRETATION: 
  From the investigation of DPPH radical scavenging assay of GANDHAGA 
PARPAM  it was concluded that the test drug has shown promising antioxidant activity 
and exhibits significant percentage inhibition against DPPH radicals when compared 
to that of standard BHT. Because of this high antioxidant therapeutic nature the drug 
GANDHAGA PARPAM  will helps to treat cancer. Antioxidants play a major role in 
the treatment of cancer.  
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EVALUATION OF ANTI-INFLAMMATORY  ACTIVITY OF GANTHAGA 
PARPAM BY CARRAGEENAN INDUCED  HINDPAW OEDEMA METHOD 
TABLE No. 22 Anti-inflammatory activity of Gandhaga Parpam 
 
Serial 
no 
Name of 
drugs/groups 
Dose/100 
gram 
body 
weight 
Initial 
reading 
average 
final 
reading 
average 
Mean 
difference 
Percentage 
inflammation 
Percentage 
inhibition 
1 Water 2 ml 0.9 1.2  100 - 
2 Diclofenac 5 mg/kg 0.9 0.8 0.2 11.1 88.9 
3 GP 100mg/kg 0.8 1.1 0.30 37.5 62.5 
4 GP 200mg/kg 0.8 0.7 0.1 16.4 74.6 
* Data are expressed as Mean ± S.E.M. 
*Data were analyzed by one way ANOVA followed by Newman’s keul’s multiple 
range tests, to determine the significance of the difference between the control group 
and rats treated with the test compounds. 
*a   Values were significantly different from normal control at P< 0.01. 
Fig.No. 14 
Evaluation of Anti-Inflammatory 
 
INTERPRETATION: 
  GANTHAGA PARPAM at doses100mg/kg& 200mg/kg were tested for their 
Anti- inflammatory activity by using carrageenan Induced rat paw edema method and 
the results are tabulated in table no22. The results reveals that  GANTHAGA 
PARPAM at 100mg/kg & 200mg/kg doses possesses significant Anti- inflammatory 
activity when compared to control group at p<0.01. 
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ANTIMICROBIAL ACTIVITIES OF GANDHAGA PARPAM BY AGAR 
WELL DIFFUSION METHOD 
Table. No. 23 
S.No. Test Pathogens 
 
Result  Zone of Inhibition (mm) at 30µl 
Positive Control 
(Chloromphenical) Size of Inhibition 
1. Escherichia coli Sensitive  25 mm 20 mm 
2 Staphylococcus aureus Sensitive 20 mm 10 mm 
3 Klebsiella pneumoniae Sensitive  20 mm 10 mm 
4 Pseudomonas aeruginosa Resistant 23 mm 5 mm 
5. Candida sp (Ketaconozole) Sensitive 24 mm 8 mm  
 
Fig. No. 15 
Antimicrobial activity result 
 
S.No. Bacterial Pathogens Plates 
1. Escherichia coli 
  
2. Staphylococcu aureus 
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3. Klebsiella sps. 
 
 
4. Pseudomonas aeruginosa 
 
5. Candida sp 
 
 
INTERPRETATION :  
  Both gram positive, gram negative  bacteria E.Coli, Klebsiella, Pneumonia  
and Staphylococcus aureus and fungus Candida species were found to be sensitive 
when compared to the standard drug Chloromphenica and Ketaconozole. The bacteria 
Pseudomona aeruginosa were found to be resistance. The mineral drug GANDHAGA 
PARPAM exhibited broad spectrum activity against bacterial and fungal pathogenes at 
100 mg/ml concentration of the drug. 
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7. SUMMARY 
  The test drug Ganthaga Parpam is selected from the text Agasthiyar Vaithiya 
Vallathy 600,Pg.No.218&219 Authored by Dr.K.Velusamy,MD(S).,for the evaluation 
of Anti-Cancerous,Anti-Oxidant and Anti-Inflammatory activities. 
  The review literature reveals that the ganthagam and Odukkan have                       
anti-tumour, anti-oxidant and anti-inflammatory activites. 
Aim of the dissertation is to study the Anti-cancer,Anti-oxidant and  Anti-
inflammatory activities. 
  The test drug was prepared properly by given procedure. All the ingredients 
were identified and authenticated by expert of department of gunapadam. 
  The preparation of trial drug was standardized primarily by physicochemical 
analysis of the drug shows it is grey in colour with bitter astringent taste and odour. 
  As per the siddha literature diseases are caused due to change in derangement 
of three vital humours, the vital humour kabha is deranged and accompanied with  
ushna causes yoni puttru. The bitter taste normalized ushnam and kapham. 
  In physicochemical analysis, the water soluble ash value of the test drug 
is7.75% and acid soluble ash value is 0.95%.The loss on drying of the drug is7.30%. 
  The biochemical analysis shows the presence of sulphate and chloride. These 
content are having important role in physiological functions of the body.  Microbial 
limit test shows it is free from microbial contamination. 
  The phytochemical analysis reveals the presence of alkaloid, tannins, 
carboxylates and glycosides, Alkaloids are having stimulant activities which controls 
the fatigue and lethargy of the cancer patients. Tannins having astringent, 
haemostatic, anti-septic and toxic properties, which control symptoms of cervical 
cancer. 
  In instrumental analysis the ICP-OES result shows the toxic heavy metals such 
as Al, As, Cd, Cu Ni and Pb are in below detection limit (BDL). It is evident that the 
safety of siddha medicine has been proved by the modern scientific way. 
  The FTIR shows the presence of Alkane, Carbon di oxide, Bromide, Iodide  
  SEM analysis of GANDHAGA PARPAM shows that the uniform distribution 
of particle present size is 20-40 which increase the efficacy and bioavailability of test 
drug. So very minimal quantity of medicine is enough to treat the disease. 
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Anti-cancerous activity  study was carried out for GANDHAGA PARPAM by 
Dalton’s Lymphoma ascites (DLA) cell was supplied by Amala cancer research 
center, Trissur, Kerala, India. The cells maintained in vivo in Swiss albino mice by 
intraperitoneal transplantation. While transforming the tumor cells to the grouped 
animal the DLA cells were aspirated from peritoneal cavity of the mice using saline. 
The cell counts were done and further dilution were made so that total cell should be 1 
x 106, this dilution was given intraperitonealy. Let the tumor grow in the mice for 
minimum seven days before starting treatments. The result shows that GANDHAGA 
PARPAM 200mg/kg in DLA tumor bearing mice. The GP at the dose of  200mg/kg 
significantly inhibited the tumour volume, PCV, Tumour viable cell count and 
brought back the haematological parameter to more or less normal level. 
   The result showed that there was a concentration dependant anti-oxidant 
activity of  GANDHAGA PARPAM. At the concentration [1.25-20µgm/ml] Percentage 
of inhibition increased from 9.8 to 88%. At the concentration of 20 µgm/ml there was 
an increased percentage of inhibition(88%) is scavenging the free radicals(DPPH). 
  The IC 50 value was obtained at 10µgm/ml.It is showed that GANDHAGA 
PARPAM is having significant anti oxidant activity. 
  Microbiology analysis result shows that GP controls bacterial cause of 
Chronic non healing cervical ulcer which is one of the causative factor  of cancer. 
  The acute toxicity study shows that GANDHAGA PARPAM did not produce 
any toxic effect at dose of 5mg/kg, 50mg/kg, 300mg/kg, 1000mg/kg, and 2000mg/kg . 
  In sub acute toxicity test drug GANDHAGA PARPAM is did not cause either 
any lethality or adverse changes with general behavior of rats and also there were no 
observable changes in hematological and biochemical parameter (50 to 200mg/kg 
body weight) over a period of 28 days. our result have demonstrated that  the  
GANDHAGA PARPAM is relatively safe when administrated orally in rats. 
  It has been conducted that the GANDHAGA PARPAM is very effective in 
treating yoni putru(cervical cancer) without causing any adverse effects. 
 
  
  
   141 PRE CLINICAL  STUDY OF  GANDHAGA PARPAM 
 
  
8. CONCLUSION 
 
 The trial drug  GANDHAGA PARPAM  is a herbo mineral, selected from the 
text book of Agathiyar Vaithiya Vallathy - 600, P.No. 218, 219 authored by 
Dr.A.Velusamy, MD.(s).,  for Anti-cancerous, Anti-oxidant and Anti-inflammatory 
Activities and the results supported the study. 
 From the literature review, physico-chemical analysis, Bio-Chemical analysis, 
Pharamacological studies, Microbiological analysis, Instrumental analysis and 
toxicological studies it is concluded that the test drug of  GP  is safe and effective for 
all type of cancer (Yoni Puttru) and in safer to continue even for a long duration. 
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9. FUTURE SCOPE 
 
  Preclinical evaluation of the test drug  GANDHAGA PARPAM  has been done 
by bio-chemical, physio-chemical, instrumental, pharmacological, toxicological and 
microbial standard prescribed procedures. In future the drug has to validated by 
extensive  clinical trials as per WHO guidelines. This GANDHAGA PARPAM  is to be 
used very much to treating all types of cancer. 
  Having made up of nano particles, GANDHAGA PARPAM  holds extra 
ordinary promise for the presentation and treatment of cancer. Thus the ancient 
wisdom siddhars will remains as one important source of future medicine and 
therapeutics 
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